Document:

trtc_ex103.htm

EXHIBIT 10.3
  
 Option No.   
  
 Employee Form
   
 TERRA TECH CORP.
  
 Stock Option Grant Notice
  
 Stock Option Grant under the Company’s
 Amended and Restated 2018 Equity Incentive Plan
  
 	 1.
	 Name and Address of Participant:
	  
	 Tiffany Davis

	  
	  
	  
	  

	  
	  
	  
	 _________________

	  
	  
	  
	  

	  
	  
	  
	 _________________

	  
	  
	  
	  

	 2.
	 Date of Option Grant:
	  
	 April 6, 2021

	  
	  
	  
	  

	 3.
	 Type of Grant:
	  
	 Non-qualified

	  
	  
	  
	  

	 4.
	 Maximum Number of Shares for which this Option is exercisable:
	  
	 409,716

	  
	  
	  
	  

	 5.
	 Exercise (purchase) price per Share:
	  
	 $0.2847 per Share

	  
	  
	  
	  

	 6.
	 Option Expiration Date:
	  
	 April 5, 2031

	  
	  
	  
	  

	 7.
	 Vesting Start Date:
	  
	 April 6, 2021

	  
	  
	  
	  

	 8.
	 Vesting Schedule: This Option shall become exercisable (and the Shares issued upon exercise shall be vested) as follows; provided the Participant is an Employee, director or Consultant of the Company or of an Affiliate on the applicable vesting date:

 
   
 The Options vest in ten installments, with the first installment of 34,722 Shares vesting on April 6, 2021, and the remaining installments vesting equally on the first day of each month thereafter.
  
 The foregoing rights are cumulative and are subject to the other terms and conditions of this Agreement and the Plan. 
  
 	 
	1
	

	 

 
  
 The Company and the Participant acknowledge receipt of this Stock Option Grant Notice and agree to the terms of the Stock Option Agreement attached hereto and incorporated by reference herein, the Company’s 2018 Amended and Restated Equity Incentive Plan and the terms of this Option Grant as set forth above.
  
 	 	TERRA TECH CORP. 	
	 	 	 	 
		By:	/s/ Francis Knuettel II 	
	  
	  
	Name: Francis Knuettel II	 
	 	 	Title: CEO/President	 
	 	 	 	 
	  
	 /s/ Tiffany Davis
	  

	  
	 Tiffany Davis 
	  

 
  
 	 
	2
	

	 

 
  
 TERRA TECH CORP.
  
 STOCK OPTION AGREEMENT - INCORPORATED TERMS AND CONDITIONS
   
 AGREEMENT made as of the date of grant set forth in the Stock Option Grant Notice by and between Terra Tech Corp. (the “Company”), a Nevada corporation, and the individual whose name appears on the Stock Option Grant Notice (the “Participant”).
  
 WHEREAS, the Company desires to grant to the Participant an Option to purchase shares of its common stock, $.001 par value per share (the “Shares”), under and for the purposes set forth in the Company’s Amended and Restated 2018 Equity Incentive Plan (the “Plan”);
  
 WHEREAS, the Company and the Participant understand and agree that any terms used and not defined herein have the same meanings as in the Plan; and
  
 WHEREAS, the Company and the Participant each intend that the Option granted herein shall be of the type set forth in the Stock Option Grant Notice.
  
 NOW, THEREFORE, in consideration of the mutual covenants hereinafter set forth and for other good and valuable consideration, the parties hereto agree as follows:
  
 1. GRANT OF OPTION. The Company hereby grants to the Participant the right and option to purchase all or any part of an aggregate of the number of Shares set forth in the Stock Option Grant Notice, on the terms and conditions and subject to all the limitations set forth herein, under United States securities and tax laws, and in the Plan, which is incorporated herein by reference. The Participant acknowledges receipt of a copy of the Plan.
  
 2. EXERCISE PRICE. The exercise price of the Shares covered by the Option shall be the amount per Share set forth in the Stock Option Grant Notice, subject to adjustment, as provided in the Plan, in the event of a stock split, reverse stock split or other events affecting the holders of Shares after the date hereof (the “Exercise Price”). Payment shall be made in accordance with Paragraph 10 of the Plan.
  
 3. EXERCISABILITY OF OPTION. Subject to the terms and conditions set forth in this Agreement and the Plan, the Option granted hereby shall become vested and exercisable as set forth in the Stock Option Grant Notice and is subject to the other terms and conditions of this Agreement and the Plan.
  
 4. TERM OF OPTION. This Option shall terminate on the Option Expiration Date as specified in the Stock Option Grant Notice, but shall be subject to earlier termination as provided herein or in the Plan.
  
 If the Participant ceases to be an Employee, director or Consultant of the Company or of an Affiliate for any reason other than the death or Disability of the Participant, or termination of the Participant for Cause (the “Termination Date”), the Option to the extent then vested and exercisable pursuant to Section 3 hereof as of the Termination Date, and not previously terminated in accordance with this Agreement, may be exercised within three months after the Termination Date, or on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice, whichever is earlier, but may not be exercised thereafter except as set forth below. In such event, the unvested portion of the Option shall not be exercisable and shall expire and be cancelled on the Termination Date.
  
 	 
	3
	

	 

 
  
 In the event of the Participant’s Disability or death within three months after the Termination Date, the Participant or the Participant’s Survivors may exercise the Option within one year after the Termination Date, but in no event after the Option Expiration Date as specified in the Stock Option Grant Notice.
  
 In the event the Participant’s service is terminated by the Company or an Affiliate for Cause, the Participant’s right to exercise any unexercised portion of this Option even if vested shall cease immediately as of the time the Participant is notified his or her service is terminated for Cause, and this Option shall thereupon terminate. Notwithstanding anything herein to the contrary, if subsequent to the Participant’s termination, but prior to the exercise of the Option, the Administrator determines that, either prior or subsequent to the Participant’s termination, the Participant engaged in conduct which would constitute Cause, then the Participant shall immediately cease to have any right to exercise the Option and this Option shall thereupon terminate.
  
 In the event of the Disability of the Participant, as determined in accordance with the Plan, the Option shall be exercisable within one year after the Participant’s termination of service due to Disability or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event, the Option shall be exercisable:
  
 	  
	 (a) 
	 to the extent that the Option has become exercisable but has not been exercised as of the date of the Participant’s termination of service due to Disability; and

	  
	  
	  

	  
	 (b) 
	 in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the date of the Participant’s termination of service due to Disability of any additional vesting rights that would have accrued on the next vesting date had the Participant not become Disabled. The proration shall be based upon the number of days accrued in the current vesting period prior to the date of the Participant’s termination of service due to Disability.

 
   
 In the event of the death of the Participant while an Employee, director or Consultant of the Company or of an Affiliate, the Option shall be exercisable by the Participant’s Survivors within one year after the date of death of the Participant or, if earlier, on or prior to the Option Expiration Date as specified in the Stock Option Grant Notice. In such event, the Option shall be exercisable:
  
 	  
	 (x) 
	to the extent that the Option has become exercisable but has not been exercised as of the date of death; and
	  
	  
	  

	  
	 (y) 
	 in the event rights to exercise the Option accrue periodically, to the extent of a pro rata portion through the date of death of any additional vesting rights that would have accrued on the next vesting date had the Participant not died. The proration shall be based upon the number of days accrued in the current vesting period prior to the Participant’s date of death.

 
   
 	 
	4
	

	 

 
  
 5. METHOD OF EXERCISING OPTION. Subject to the terms and conditions of this Agreement, the Option may be exercised by written notice to the Company or its designee, in substantially the form of Exhibit A attached hereto (or in such other form acceptable to the Company, which may include electronic notice). Such notice shall state the number of Shares with respect to which the Option is being exercised and shall be signed by the person exercising the Option (which signature may be provided electronically in a form acceptable to the Company). Payment of the Exercise Price for such Shares shall be made in accordance with Paragraph 10 of the Plan. The Company shall deliver such Shares as soon as practicable after the notice shall be received, provided, however, that the Company may delay issuance of such Shares until completion of any action or obtaining of any consent, which the Company deems necessary under any applicable law (including, without limitation, state securities or “blue sky” laws). The Shares as to which the Option shall have been so exercised shall be registered in the Company’s share register in the name of the person so exercising the Option (or, if the Option shall be exercised by the Participant and if the Participant shall so request in the notice exercising the Option, shall be registered in the Company’s share register in the name of the Participant and another person jointly, with right of survivorship) and shall be delivered as provided above to or upon the written order of the person exercising the Option. In the event the Option shall be exercised, pursuant to Section 4 hereof, by any person other than the Participant, such notice shall be accompanied by appropriate proof of the right of such person to exercise the Option. All Shares that shall be purchased upon the exercise of the Option as provided herein shall be fully paid and nonassessable.
  
 6. PARTIAL EXERCISE. Exercise of this Option to the extent above stated may be made in part at any time and from time to time within the above limits, except that no fractional share shall be issued pursuant to this Option.
  
 7. NON‐ASSIGNABILITY. The Option shall not be transferable by the Participant otherwise than by will, by the laws of descent and distribution or pursuant to a qualified domestic relations order as defined by the Code or Title I of the Employee Retirement Income Security Act or the rules thereunder. Such transferee shall remain subject to all the terms and conditions applicable to the Option prior to such transfer and each such transferee shall so acknowledge in writing as a condition precedent to the effectiveness of such transfer. The term “Immediate Family” shall mean the Participant’s spouse, former spouse, parents, children, stepchildren, adoptive relationships, sisters, brothers, nieces, nephews and grandchildren (and, for this purpose, shall also include the Participant). Except as provided above in this paragraph, the Option shall be exercisable, during the Participant’s lifetime, only by the Participant (or, in the event of legal incapacity or incompetency, by the Participant’s guardian or representative) and shall not be assigned, pledged or hypothecated in any way (whether by operation of law or otherwise) and shall not be subject to execution, attachment or similar process. Any attempted transfer, assignment, pledge, hypothecation or other disposition of the Option or of any rights granted hereunder contrary to the provisions of this Section 7, or the levy of any attachment or similar process upon the Option shall be null and void.
  
 	 
	5
	

	 

 
  
 8. NO RIGHTS AS STOCKHOLDER UNTIL EXERCISE. The Participant shall have no rights as a stockholder with respect to Shares subject to this Agreement until registration of the Shares in the Company’s share register in the name of the Participant. Except as is expressly provided in the Plan with respect to certain changes in the capitalization of the Company, no adjustment shall be made for dividends or similar rights for which the record date is prior to the date of such registration.
  
 9. ADJUSTMENTS. The Plan contains provisions covering the treatment of Options in a number of contingencies such as stock splits and mergers. Provisions in the Plan for adjustment with respect to stock subject to Options and the related provisions with respect to successors to the business of the Company are hereby made applicable hereunder and are incorporated herein by reference.
  
 10. TAXES. The Participant acknowledges and agrees that (i) any income or other taxes due from the Participant with respect to this Option or the Shares issuable pursuant to this Option shall be the Participant’s responsibility; (ii) the Participant was free to use professional advisors of his or her choice in connection with this Agreement, has received advice from his or her professional advisors in connection with this Agreement, understands its meaning and import, and is entering into this Agreement freely and without coercion or duress; (iii) the Participant has not received and is not relying upon any advice, representations or assurances made by or on behalf of the Company or any Affiliate or any employee of or counsel to the Company or any Affiliate regarding any tax or other effects or implications of the Option, the Shares or other matters contemplated by this Agreement; and (iv) neither the Administrator, the Company, its Affiliates, nor any of its officers or directors, shall be held liable for any applicable costs, taxes, or penalties associated with the Option if, in fact, the Internal Revenue Service were to determine that the Option constitutes deferred compensation under Section 409A of the Code.
  
 The Participant agrees that the Company may withhold from the Participant’s remuneration, if any, the minimum statutory amount of federal, state and local withholding taxes attributable to such amount that is considered compensation includable in such person’s gross income. At the Company’s discretion, the amount required to be withheld may be withheld in cash from such remuneration, or in kind from the Shares otherwise deliverable to the Participant on exercise of the Option. The Participant further agrees that, if the Company does not withhold an amount from the Participant’s remuneration sufficient to satisfy the Company’s income tax withholding obligation, the Participant will reimburse the Company on demand, in cash, for the amount under-withheld.
  
 11. PURCHASE FOR INVESTMENT. Unless the offering and sale of the Shares to be issued upon the particular exercise of the Option shall have been effectively registered under the Securities Act, the Company shall be under no obligation to issue the Shares covered by such exercise unless the Company has determined that such exercise and issuance would be exempt from the registration requirements of the Securities Act and until the following conditions have been fulfilled:
  
 	  
	 (a) 
	 The person(s) who exercise the Option shall warrant to the Company, at the time of such exercise, that such person(s) are acquiring such Shares for their own respective accounts, for investment, and not with a view to, or for sale in connection with, the distribution of any such Shares, in which event the person(s) acquiring such Shares shall be bound by the provisions of the following legend which shall be endorsed upon any certificate(s) evidencing the Shares issued pursuant to such exercise:

 
   
 	 
	6
	

	 

 
   
 	  
	  
	 “The shares represented by this certificate have been taken for investment and they may not be sold or otherwise transferred by any person, including a pledgee, unless (1) either (a) a Registration Statement with respect to such shares shall be effective under the Securities Act of 1933, as amended, or (b) the Company shall have received an opinion of counsel satisfactory to it that an exemption from registration under such Act is then available, and (2) there shall have been compliance with all applicable state securities laws;” and

	  
	  
	  

	  
	 (b) 
	 If the Company so requires, the Company shall have received an opinion of its counsel that the Shares may be issued upon such particular exercise in compliance with the Securities Act without registration thereunder. Without limiting the generality of the foregoing, the Company may delay issuance of the Shares until completion of any action or obtaining of any consent, which the Company deems necessary under any applicable law (including without limitation state securities or “blue sky” laws).

 
  
 12. RESTRICTIONS ON TRANSFER OF SHARES.
  
 	  
	 (a) 
	 The Participant agrees that in the event the Company proposes to offer for sale to the public any of its equity securities and such Participant is requested by the Company and any underwriter engaged by the Company in connection with such offering to sign an agreement restricting the sale or other transfer of Shares, then it will promptly sign such agreement and will not transfer, whether in privately negotiated transactions or to the public in open market transactions or otherwise, any Shares or other securities of the Company held by him or her during such period as is determined by the Company and the underwriters, not to exceed 180 days following the closing of the offering, plus such additional period of time as may be required to comply with FINRA rules or similar rules thereto promulgated by another regulatory authority (such period, the “Lock-Up Period”). Such agreement shall be in writing and in form and substance reasonably satisfactory to the Company and such underwriter and pursuant to customary and prevailing terms and conditions. Notwithstanding whether the Participant has signed such an agreement, the Company may impose stop-transfer instructions with respect to the Shares or other securities of the Company subject to the foregoing restrictions until the end of the Lock-Up Period.

 
    
 	 
	7
	

	 

 
  
 	  
	 (b) 
	 The Participant acknowledges and agrees that neither the Company, its stockholders nor its directors and officers, has any duty or obligation to disclose to the Participant any material information regarding the business of the Company or affecting the value of the Shares before, at the time of, or following a termination of the service of the Participant by the Company, including, without limitation, any information concerning plans for the Company to make a public offering of its securities or to be acquired by or merged with or into another firm or entity.

 
  
 13. NO OBLIGATION TO MAINTAIN RELATIONSHIP. The Participant acknowledges that: (i) the Company is not by the Plan or this Option obligated to continue the Participant as an employee, director or Consultant of the Company or an Affiliate; (ii) the Plan is discretionary in nature and may be suspended or terminated by the Company at any time; (iii) the grant of the Option is a one-time benefit which does not create any contractual or other right to receive future grants of options, or benefits in lieu of options; (iv) all determinations with respect to any such future grants, including, but not limited to, the times when options shall be granted, the number of shares subject to each option, the option price, and the time or times when each option shall be exercisable, will be at the sole discretion of the Company; (v) the Participant’s participation in the Plan is voluntary; (vi) the value of the Option is an extraordinary item of compensation which is outside the scope of the Participant’s employment or consulting contract, if any; and (vii) the Option is not part of normal or expected compensation for purposes of calculating any severance, resignation, redundancy, end of service payments, bonuses, long-service awards, pension or retirement benefits or similar payments.
  
 14. NOTICES. Any notices required or permitted by the terms of this Agreement or the Plan shall be given by recognized courier service, facsimile, registered or certified mail, return receipt requested, addressed as follows:
  
 If to the Company: 
  
 Terra Tech Corp. 
 3242 S. Halladay St., Suite 202
 Santa Ana, CA 92705
 Attention: Chief Financial Officer and General Counsel
  
 If to the Participant at the address set forth on the Stock Option Grant Notice 
  
 or to such other address or addresses of which notice in the same manner has previously been given. Any such notice shall be deemed to have been given upon the earlier of receipt, one business day following delivery to a recognized courier service or three business days following mailing by registered or certified mail.
  
 15. GOVERNING LAW. This Agreement shall be governed by and construed in accordance with the laws of the State of Nevada, without giving effect to the conflict of law principles thereof. For the purpose of litigating any dispute that arises under this Agreement, the parties hereby consent to exclusive jurisdiction in Nevada and agree that such litigation shall be conducted in the state courts of Clark County, Nevada or the federal courts of the United States for the District of Nevada.
  
 	 
	8
	

	 

 
  
 16. BENEFIT OF AGREEMENT. Subject to the provisions of the Plan and the other provisions hereof, this Agreement shall be for the benefit of and shall be binding upon the heirs, executors, administrators, successors and assigns of the parties hereto.
  
 17. ENTIRE AGREEMENT. This Agreement, together with the Plan, embodies the entire agreement and understanding between the parties hereto with respect to the subject matter hereof and supersedes all prior oral or written agreements and understandings relating to the subject matter hereof (with the exception of acceleration of vesting provisions contained in any other agreement with the Company). No statement, representation, warranty, covenant or agreement not expressly set forth in this Agreement shall affect or be used to interpret, change or restrict, the express terms and provisions of this Agreement. Notwithstanding the foregoing in all events, this Agreement shall be subject to and governed by the Plan.
  
 18. MODIFICATIONS AND AMENDMENTS. The terms and provisions of this Agreement may be modified or amended as provided in the Plan.
  
 19. WAIVERS AND CONSENTS. Except as provided in the Plan, the terms and provisions of this Agreement may be waived, or consent for the departure therefrom granted, only by written document executed by the party entitled to the benefits of such terms or provisions. No such waiver or consent shall be deemed to be or shall constitute a waiver or consent with respect to any other terms or provisions of this Agreement, whether or not similar. Each such waiver or consent shall be effective only in the specific instance and for the purpose for which it was given, and shall not constitute a continuing waiver or consent.
  
 20. DATA PRIVACY. By entering into this Agreement, the Participant: (i) authorizes the Company and each Affiliate, and any agent of the Company or any Affiliate administering the Plan or providing Plan recordkeeping services, to disclose to the Company or any of its Affiliates such information and data as the Company or any such Affiliate shall request in order to facilitate the grant of options and the administration of the Plan; (ii) to the extent permitted by applicable law waives any data privacy rights he or she may have with respect to such information, and (iii) authorizes the Company and each Affiliate to store and transmit such information in electronic form for the purposes set forth in this Agreement.
  
 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]
  
 	 
	9
	

	

 
  
 Exhibit A
  
 NOTICE OF EXERCISE OF STOCK OPTION
  
 To: Terra Tech Corp.
  
 IMPORTANT NOTICE: This form of Notice of Exercise may only be used at such time as the Company has filed a Registration Statement with the Securities and Exchange Commission under which the issuance of the Shares for which this exercise is being made is registered and such Registration Statement remains effective.
  
 Ladies and Gentlemen:
  
 I hereby exercise my Stock Option to purchase _________ shares (the “Shares”) of the common stock, $.001 par value, of Terra Tech Corp. (the “Company”), at the exercise price of $________ per share, pursuant to and subject to the terms of that Stock Option Grant Notice dated _______________, 20__.
  
 I understand the nature of the investment I am making and the financial risks thereof. I am aware that it is my responsibility to have consulted with competent tax and legal advisors about the relevant national, state and local income tax and securities laws affecting the exercise of the Option and the purchase and subsequent sale of the Shares.
  
 I am paying the option exercise price for the Shares as follows:
  
 _________________________________________
  
 Please issue the Shares (check one):
  
 ☐   to me; or 
 ☐   to me and ____________________________, as joint tenants with right of survivorship, at the following address:
   
 	  
	  
	  

	  
	  
	  

	  
	  
	  

 
  
 Exhibit A-1
  
 	
	  

	

	 

 
  
 My mailing address for stockholder communications, if different from the address listed above, is:
   
 	  
	  
	  

	  
	  
	  

	  
	  
	  

 
  
 	 		Very truly yours,	
	 	 	 	 
				
	  
	  
	Participant (signature)	 
	 	 		 
	  
	  
	  
	  

	  
	  
	 Print Name
	  

	 	 	 	 
	  
	  
	  
	  

	  
	  
	 Date
	  

 
  
 Exhibit A-2EX-10.3

 Exhibit 10.3 

[***] = CERTAIN CONFIDENTIAL INFORMATION CONTAINED IN THIS DOCUMENT, MARKED BY BRACKETS, IS OMITTED BECAUSE IT IS BOTH (I) NOT MATERIAL AND (II)
CUSTOMARILY AND ACTUALLY TREATED BY THE REGISTRANT AS PRIVATE OR CONFIDENTIAL. 
 CONFIDENTIAL 

 
 SUPPLY AGREEMENT 

THIS SUPPLY AGREEMENT (the “Agreement”), which shall become effective in
accordance with Section 10.1, is entered into by and between DYNAVAX TECHNOLOGIES CORPORATION, a Delaware corporation, with a place of business located at 2100 Powell Street,
Suite 900, Emeryville, CA 94608, USA (“Dynavax”), and VALNEVA SCOTLAND LIMITED, a company organized under the laws of Scotland, with its principal place of business
at Oakbank Park Rd, Livingston EH53 0TG, United Kingdom (“Purchaser”), and VALNEVA AUSTRIA GMBH, a company registered in Austria (company number FN 389960 x /HG
Wien) whose registered address is at Campus Vienna Biocenter 3, 1030 Vienna, Austria (“Valneva Austria”). Dynavax and Purchaser may be referred to herein individually as a “Party” or collectively as the
“Parties”. 
 RECITALS 

WHEREAS, Dynavax, a biopharmaceutical company, has developed a proprietary
toll-like receptor 9 (TLR9) agonist adjuvant known as CpG 1018; 

WHEREAS, Purchaser is a specialty vaccine company engaged in the development, manufacture and
commercialization of vaccines for the prevention of diseases with major unmet medical needs; and 

WHEREAS, Valneva has developed a proprietary vaccine for the prevention of
COVID-19, the disease caused by SARS-CoV-2 and Valneva Austria wishes to undertake clinical testing of and commercialize that
vaccine initially in the UK under an agreement with the UK Government. 
 WHEREAS Purchaser wishes to purchase and use
Dynavax’s proprietary adjuvant for the purposes of commercialisation of Purchaser’s vaccine and Dynavax wishes to supply specified quantities of such adjuvant to Purchaser for such use, on the terms and conditions set forth below. 

NOW, THEREFORE, in consideration of the foregoing premises and the mutual covenants
contained herein, and for other good and valuable consideration, the receipt and sufficiency of which are hereby acknowledged, the Parties agree as follows: 

ARTICLE 1 
 DEFINITIONS

 1.1 “Affiliate” means, with respect to any Party, any entity that, directly or indirectly through one
or more intermediaries, controls, is controlled by, or is under common control with such Party, but for only so long as such control exists. As used in this Section 0, “control” means (a) to possess, directly or indirectly, the
power to direct the management or policies of an entity, whether through ownership of voting securities, by contract relating to voting rights or corporate governance; or (b) direct or indirect beneficial ownership of more than fifty percent
(50%) (or such lesser percentage which is the maximum allowed to be owned by a foreign corporation in a particular jurisdiction) of the voting share capital or other equity interest in such entity. 

 CONFIDENTIAL 
  

 1.2 “Anti-Corruption Laws” means the U.S. Foreign Corrupt Practices
Act (15 U.S.C. §§78dd-1, et. seq.), as amended (the “FCPA”), the Organization for Economic Co-operation and Development (OECD) Convention on
combating bribery of foreign public officials in international business transactions, the UK Bribery Act 2010, as amended, and any subordinate legislation made under the FCPA or the UK Bribery Act 2010 from time to time together with any guidance
and/or codes of practice issued by the relevant government department concerning the legislation, and any other Applicable Laws of similar effect, and the related regulations and published interpretations thereunder. “Applicable
Laws” means the applicable provisions of any and all national, supranational, regional, state, and local laws, treaties, statutes, rules, regulations, administrative codes, guidance, or other requirements of any Government Authority having
jurisdiction over or related to the subject item or activity or Party. 
 1.3 “Batch” means the specific quantity of
CpG Material produced in a single manufacturing production run. 
 1.4 “Bioequivalent Version” means, with respect
to the CpG Adjuvant, [***]. 
 1.5 “Biosimilar Version” means, with respect to a Product that is being sold
in a country or regulatory jurisdiction worldwide (the “Reference Product”), a biopharmaceutical product sold by a Third Party (other than a Third Party acting on behalf of or in concert with Purchaser or Dynavax or any Affiliate or
sublicensee or assignee of Dynavax or Purchaser) in such country or regulatory jurisdiction worldwide that through reference to the regulatory approval of the Reference Product, is eligible for and has achieved regulatory approval in such country or
regulatory jurisdiction pursuant to an abbreviated follow-on biological approval pathway established by the regulatory authority in such country or regulatory jurisdiction pursuant to the applicable law, or otherwise is approved for marketing and
sale in such country or regulatory jurisdiction by an abridged procedure in reliance, in whole or in part, on the prior regulatory approval of the Reference Product or on the safety and efficacy data generated for the prior regulatory approval (in
such country or regulatory jurisdiction) of the Reference Product, including any such biopharmaceutical product that (i) with respect to such biopharmaceutical product in the United States, has been approved as a biosimilar or interchangeable
product by the FDA pursuant to 42 U.S.C. § 262 of the Public Health Service Act, (ii) with respect to such biopharmaceutical product subject to the regulatory jurisdiction of the EMA, has been approved as a similar biological medicine
product by EMA as described in CHMP/437/04, issued 30 October 2005, as may be amended, or any subsequent or superseding law, statute or regulation or (iii) with respect to such biopharmaceutical product outside the United States and in a
country which is not subject to the regulatory jurisdiction of the EMA, has otherwise obtained Regulatory Approval from a regulatory authority pursuant to similar statutory or regulatory requirement as that described in the foregoing subsections
(i) and (ii) in such other country or regulatory jurisdiction. 
 1.6 “Business Day” means each day of
the week excluding Saturday, Sunday, and a day on which banking institutions in San Francisco, CA, USA, Edinburgh, Scotland or Vienna, Austria, are closed. 

  
 2 

 CONFIDENTIAL 
  

 1.7 “Calendar Quarter” means each of the three (3) month
periods ending March 31 (“Q1”), June 30 (“Q2”), September 30 (“Q3”), and December 31 (“Q4”); except that (a) the first Calendar Quarter of the Term shall
begin on the Effective Date and end on the first to occur of March 31, June 30, September 30, and December 31 thereafter; and (b) the final Calendar Quarter of the Term shall end on the last day of the Term. 

1.8 “Calendar Year” means each successive period of twelve (12) consecutive calendar months ending on
December 31; except that (a) the first Calendar Year of the Term shall begin on the Effective Date and end on December 31 of the calendar year in which the Effective Date falls, and (b) the final Calendar Year of the Term shall end on
the last day of the Term. 
 1.9 “Certificate of Analysis” means the written certification specifying that
the relevant analytical test results confirm that a specific Batch of CpG Material delivered complies with the applicable Specifications. 

1.10 “Certificate of Conformance” means the written certification specifying that a specific Batch of CpG
Material delivered meets the applicable Specifications and that such Batch has been manufactured in compliance with GMP. 
 1.11
“CMO” means contract manufacturing organization. 
 1.12 “Collaboration Agreements” means
(i) the Clinical Collaboration Agreement dated 31 July 2020 between Dynavax and Valneva Austria, and (ii) the Collaboration Agreement dated 15 April 2020 between Dynavax and Valneva Austria, as amended by Amendment No. 1 dated
29 July 2020; in each case, as amended from time to time. 
 1.13 “Confidential Information” means all non-public information owned or controlled by one Party or any of its Affiliates (together, the “Disclosing Party”) and disclosed or made available to the other Party or any of its Affiliates
(together, the “Receiving Party”) in connection with this Agreement. For clarity, all Dynavax Know-How is the Confidential Information of Dynavax, and the terms of this Agreement shall be
deemed the Confidential Information of both Parties. 
 1.14 “Cost per Dose” means the purchase price for one
Dose of CpG Material based on the Dose Assumption, as set forth in Exhibit C. For clarity, the Cost per Dose is determined based on the actual quantity of CpG Material included within a Dose. In addition to the Cost per Dose based on the Dose
Assumption, Exhibit C also includes the Cost per Dose based on a Dose containing [***] mg and [***] mg of CpG Material. 

1.15 “COVID-19” means the disease caused by SARS-CoV-2. 
 1.16 “CpG Adjuvant” means Dynavax’s proprietary
toll-like receptor 9 (TLR9) agonist adjuvant referred to by Dynavax as CpG 1018, as described in more detail in Exhibit A. 

1.17 “CpG Material” means the CpG Adjuvant [***], as described in more detail in Exhibit A. 

  
 3 

 CONFIDENTIAL 
  

 1.18 “CTA” means a clinical trial authorisation filed with the
applicable Regulatory Authority in a country or jurisdiction, which application is required to commence human clinical trials in the applicable country or jurisdiction. 

1.19 “Disclosing Party” has the meaning set forth in Section 1.13. 

1.20 “Dose” means the quantity (in milligrams) of CpG Material used in a single unit of Product, net of any overage.

 1.21 “Dose Assumption” means the quantity, in milligrams, of CpG Material that the Parties expect to be
included within a single Dose, which as of the Effective Date is [***] mg. 
 1.22 “Dynavax Know-How” means all Know-How owned or controlled by Dynavax as of the Effective Date or during the Term that is necessary for the use, sale, offer for sale, export,
or import, of the CpG Material as incorporated into any Product. 
 1.23 “Dynavax Patents” means any and all
Patents owned or controlled by Dynavax as of the Effective Date or during the Term that claim any Dynavax Know-How or the CpG Material, including the composition or any formulation thereof and any method of
making or using CpG Material. 
 1.24 “Dynavax Technology” means the Dynavax
Know-How and Dynavax Patents, including Dynavax Foreground IP. 
 1.25 “Export
Control Laws” means (a) all applicable U.S. laws and regulations relating to sanctions and embargoes imposed by U.S. Department of Treasury’s Office of Foreign Assets Control (or its successor office or other body having
substantially the same function); (b) all applicable U.S. export control laws, including the Arms Export Controls Act (22 U.S.C. Ch. 39), the International Emergency Economic Powers Act (50 U.S.C. §§ 1701 et seq.), the Trading With the
Enemy Act (50 U.S.C. app. §§ 1 et seq.), the Export Administration Act of 1979 (50 U.S.C. app. §§ 2401 et seq.), International Boycott Provisions of Section 999 of the U.S. Internal Revenue Code of 1986, and all rules,
regulations and executive orders relating to any of the foregoing, including the International Traffic in Arms Regulations (22 C.F.R. §§ 120 et seq.), the Export Administration Regulations (15 C.F.R. §§ 730 et. seq.), and the
regulations administered by the Office of Foreign Assets Controls of the United States Department of the Treasury; and (c) all export controls imposed on any goods by any country or organization or nation within the jurisdiction of which either
Party operates or does business. 
 1.26 “Facility” means the facility [***], which is located at [***], or, with
[***]. 
 1.27 “FDA” means the U.S. Food and Drug Administration or its successor. 

1.28 “Field” means the prevention, treatment, or amelioration of
COVID-19 in humans. 
 1.29 “GMP” means the then-current good
manufacturing practices applicable to the manufacture of CpG Material under Applicable Laws, including, (a) U.S. 21 C.F.R. Parts 210 and 211 and 21 C.F.R. Parts 600-610, and (b) (i) Directive
2003/94/EC laying down the principles and 

  
 4 

 CONFIDENTIAL 
  

 
guidelines of good manufacturing practice in respect of Medicinal Products for human use and investigational Medicinal Products for human use, (ii) Directive 2001/83/EC laying down the
principles and guidelines of good manufacturing practice for Medicinal Products; (iii) further guidance as published by the European Commission in Volume 4 (Good Manufacturing Practice) of “The Rules Governing Medical Products in the
European Union” and (iv) ICH Q7 Guideline “Good Manufacturing Practice Guidance for Active Pharmaceutical Ingredients”. 

1.30 “Government Authority” means any national, international, federal, state, provincial, or local government,
or political subdivision thereof, or any multinational organization, or any authority, agency, or commission entitled to exercise any administrative, executive, judicial, legislative, police, regulatory, or taxing authority or power, or any court or
tribunal (or any department, bureau or division thereof). 
 1.31
“Know-How” means any and all data, inventions, methods, proprietary information, processes, trade secrets, techniques and technology, whether patentable or not, but which are not known to
the public, including discoveries, formulae, materials (including chemicals), biological materials (including expression constructs, nucleic acid sequences, amino acid sequences, and cell lines), practices, test data (including pharmacological,
toxicological, pre-clinical and clinical information and test data), analytical and assay information, procedures, designs for experiments and tests, technology, instrumentation, devices, regulatory filings,
constructs, compounds, plans, diagrams, drawings, manufacturing practices, methods, models, knowledge, technology, and data (including formulation data), quality control data (including drug stability data), and descriptions, and any other type of
information, in any form whatsoever. 
 1.32 “Pandemic” means the COVID-19
pandemic as declared by the World Health Organization. 
 1.33 “Patents” means any and all: (a) patents
and patent applications (with the term patent being deemed to include an inventor’s certificate and application therefor, and utility model and design model patents and applications), (b) any foreign counterparts thereof, (c) all
divisionals, continuations, continuations in part thereof, (d) all patents issuing on any of the foregoing, and any foreign counterparts thereof, and (e) all registrations, reissues, re-examinations
(including resulting post-grant amendments to a granted patent), renewals, supplemental protection certificates, substitutions, revalidations, and extensions, supplementary protection certificates, and foreign equivalents of any of the foregoing.

 1.34 “Person” means an individual, sole proprietorship, partnership, limited partnership, limited
liability partnership, corporation, limited liability company, business trust, joint stock company, trust, unincorporated association, joint venture, or other similar entity or organization, including a government or political subdivision,
department, or agency of a government. 
 1.35 “Product” means any pharmaceutical product containing or comprising
[***]. 
 1.36 “Purchase Order” means each purchase order submitted by Purchaser for Doses of CpG Material. 

1.37 “Quality Agreement” has the meaning set forth in Section 4.1. 

  
 5 

 CONFIDENTIAL 
  

 1.38 “[***] Costs” mean all reasonable and documented out-of-pocket costs and expenses incurred by or on behalf of [***] and its Affiliates [***], include (a) the costs and expenses of [***], including [***], (b) the costs
and expenses [***], (c) the costs and expenses of [***], and (d) any [***] due to [***]. 
 1.39 “Receiving
Party” has the meaning set forth in Section 1.13. 
 1.40 “Regulatory Approval” means, with
respect to a country or other regulatory jurisdiction, any and all approvals, licenses, registrations, or authorizations of any Regulatory Authority necessary for the manufacture, use, storage, import, transport, promotion, marketing, distribution,
offer for sale, or sale of a pharmaceutical product in such country or other jurisdiction. 
 1.41 “Regulatory
Authority” means any Government Authority that has responsibility over the testing, development, manufacture, use, storage, import, transport, promotion, marketing, distribution, offer for sale, sale, or other commercialization of
pharmaceutical products in a given jurisdiction, including the FDA in the U.S. 
 1.42 “Rolling Forecast” has the
meaning set forth in Section 2.2(a). 
 1.43 “Senior Officer” means, with respect to Dynavax, the Chief
Executive Officer or his/her designee, and with respect to Purchaser, the Chief Executive Officer or his/her designee. 
 1.44
“Specifications” means the written specifications for the CpG Material, as set forth in the Quality Agreement. 

1.45 “Term” has the meaning set forth in Section 10.1. 

1.46 “Third Party” means any entity other than Dynavax or Purchaser or an Affiliate of Dynavax or Purchaser. 

1.47 “U.S.” means the United States of America, including its territories and possessions (including Puerto
Rico). 
 1.48 “Vaccine” means Purchaser’s VLA2001 inactivated, whole-virus SARS-CoV-2 vaccine candidate and, for the avoidance of doubt, does not include the CpG Adjuvant. 

1.49 “Vaccine Formulation” means the formulation containing the Vaccine and further excipients but not the CpG
Adjuvant. 
 1.50 “Vaccine Supply Agreement” has the meaning set forth in Section 3.1. 

1.51 “Valneva” means the Purchaser, Valenva Austria GmbH and any Affiliate of those parties. 

  
 6 

 CONFIDENTIAL 
  

 ARTICLE 2 

CPG MATERIAL SUPPLY 

2.1 Purchase and Sale. Pursuant to the terms and conditions of this Agreement, during the Term, (a) Dynavax (either itself
or, in accordance with the provisions of this Agreement, through its Affiliates or Third Party CMOs) shall manufacture and supply the CpG Material to Purchaser in such quantities as are determined in accordance with this Article 2, for use in the
manufacture of the Product for commercialization, manufacture and supply in the Field, and (b) subject to Dynavax complying with its obligations under the preceding clause (a) and meeting all of Purchaser’s and its Affiliates
requirements for CpG Adjuvant, as set out under this Agreement, Purchaser shall purchase from Dynavax all of Purchaser’s and its Affiliates’ requirements for CpG Adjuvant for such purpose and shall not procure or purchase, or attempt to
procure or purchase, the CpG Adjuvant [***] from any Third Party. 
 2.2 Initial Commitments and Orders. 

(a) Committed Volumes. Subject to Section 2.5 below, Purchaser will submit binding Purchase Orders for, purchase, and pay
for, and Dynavax will supply, [***] Doses (based on the Dose Assumption plus a [***] overage) of CpG Material for delivery as set out in the table below: 
  

																									
	 Number of Doses ([***] mg)
	  	First payment	 	 	Amount	 	 	Order
deadline	 	 	Amount
paid on
order
deadline	 	 	Delivery
date	 	 	Amount
paid on
delivery
date	 
	 [***]
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 [***]
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 [***]
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 

 (b) Indicative Volumes. Purchaser anticipates that it may purchase the amounts set out below
(each an “Indicative Amount”). 
  

																																					
	 	  	Indicative
Amount
([***] mg
Doses)	 	 	1st Reserv.
Fee Deadline	 	 	1st Reserv.	 	 	2nd Reserv.
Fee Deadline	 	 	2nd
Reserv.	 	 	Purchase
Order
Deadline	 	 	Purchase
Order
Payment	 	 	Delivery Deadline	 	 	Delivery
Payment	 
	 Follow On Amount
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 1st Additional Amount
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 2nd Additional Amount
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 
	 3rd Additional Amount
	  	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 	 	[***	] 
		  	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 	 	  
	  
	 

  
 7 

 CONFIDENTIAL 
  

 (c) If the Purchaser places a Purchase Order, for any Indicative Amounts (which
order shall, in the case of any of the 1st, 2nd or 3rd Additional Amounts, specify the precise volume being ordered) by the relevant Purchase Order Deadline, that order shall be a binding Purchase Order and Dynavax shall supply the relevant amount
for delivery by the relevant date. 
 (d) Reservation Fees. In respect of any Indicative Amount: 

(i) if the Purchaser on or before the 1st Reservation Fee Deadline places a Purchase Order for that Indicative Amount, no
Reservation Fee will be payable, but Purchaser shall pay for that Indicative Amount, or if the Purchaser on or before the 1st Reservation Fee Deadline notifies Dynavax in writing that it will not place a Purchase Order (“Confirmation of No
Purchase Notice”), no Reservation Fee will be payable; 
 (ii) otherwise: 

(1) the Purchaser shall pay the 1st Reservation Fee on the first Business Day after the 1st Reservation Fee Deadline and if the
Purchaser places a Purchase Order for that Indicative Amount or serves a Confirmation of No Purchase Notice on or before the 2nd Reservation Fee Deadline, no Second Reservation Fee will be payable; and 

(2) if the Purchaser neither places a Purchase Order for that Indicative Amount nor serves a Confirmation of No Purchase Notice
on or before the 2nd Reservation Fee Deadline, the Purchaser shall pay the 2nd Reservation Fee on the first Business Day after the 2nd Reservation Fee Deadline; 

(e) Status of Reservation Fees. If the Purchaser becomes liable to pay, and does pay, a Reservation Fee, Purchaser must place a
Purchase Order in respect of the relevant amount on or before the relevant Order Deadline in order to retain the right to purchase such amount, and if the Purchaser does not submit a Purchase Order in respect of such amount on or before such Order
Deadline, the Purchaser shall forfeit the Reservation Fee paid and the right to purchase such amount. If the Purchaser becomes liable to pay, and does pay, a Reservation Fee, and subsequently places a Purchase Order in respect of the relevant amount
on or before the relevant Order Deadline, the amount of the Reservation Fee paid shall be deemed to be a pre-payment of the aggregate Cost per Dose of the relevant amount and shall be deducted from any subsequent payments of that aggregate Cost per
Dose. 
 All Purchase Orders are subject to Purchaser’s cancellation rights set forth in Section 2.5 below. 

  
 8 

 CONFIDENTIAL 
  

 2.3 Further Forecasts and Orders 

(a) Rolling Forecast. On or before the first (1st) Business Day of each Calendar Quarter during the Term, Purchaser may provide
to Dynavax a rolling forecast of any quantity of Doses of CpG Material beyond those referred to in Section 2.2 that Purchaser plans to order for delivery during the following [***] Calendar Quarters (each, a “Rolling
Forecast”). Each Rolling Forecast shall be [***]. 
 (b) Further Purchase Orders. Within [***] days of receiving each
Rolling Forecast, Dynavax shall indicate whether it has the capacity to meet, and is willing to supply, any or all of the requirements set out in that forecast and, if so, the amount of the requirements in such forecast that it is willing to supply;
provided, however, that even if Dynavax has available capacity, it shall have no obligation to make such capacity or any portion thereof available to Purchaser. To the extent Dynavax indicates that it has the capacity, and is willing, to
supply, any or all of the requirements set out in that forecast, the Purchaser may within a further period of [***] days place a Purchase Order for the indicated amount, and Dynavax shall accept or reject such Purchase Order in writing within [***]
Business Days after its receipt of such Purchase Order. Upon Dynavax’s acceptance of such Purchase Order, such Purchase Order, subject to Purchaser’s cancellation rights set forth in Section 2.5, shall be a binding commitment of the
Purchaser to purchase and Dynavax to supply such amount in accordance with such Purchase Order. 
 2.4 Delivery Terms. 

(a) Delivery and Shipping Terms. Each Purchase Order will specify the delivery date(s) for the Doses ordered, provided that the
specified delivery date shall be a date no sooner than, in the case of [***] Doses of the first [***] Doses of the Committed Volumes under Section 2.2(a), [***] months from the date of such Purchase Order, and in the case of all other Purchase
Orders, [***] months from the date of such Purchase Order (“Delivery Timeline”). Dynavax shall package and label all CpG Material in accordance with Applicable Laws and deliver all CpG Material FCA (INCOTERMS 2020) the Facility, and
title and risk of loss shall pass from Dynavax to Purchaser upon the CpG Material being loaded onto the carrier’s collecting vehicle at the Facility, cleared for export. Purchaser shall be responsible for obtaining all licenses or other
authorizations for the import of such shipments, for all freight, handling, insurance, and shipping expenses for such shipments, and shall be the importer of record and responsible for all duties and taxes for import of such shipments. Dynavax shall
be responsible for obtaining all licenses or other authorizations for the export of such shipments, and Purchaser shall pay or reimburse Dynavax for all duties and taxes for the export of such shipments. At Purchaser’s request, Dynavax shall
provide to Purchaser such information as Purchaser may reasonably request to assist Purchaser in obtaining any licenses or other authorizations necessary for the import of such shipments. 

(b) [***]. Ahead of Regulatory Approval of the Product, Dynavax will use commercially reasonable efforts to ensure that the CpG
Materials shall, at the time of delivery in accordance with Section 2.4(a), [***]. 
 (c) Separate Contracts. Each
Purchase Order will constitute a separate contract for the supply of CpG Material under the terms of this Agreement (and excluding all other terms and conditions, including any set out or referred to in any Purchase Order or acceptance thereof). In
the event of a conflict between a Purchase Order (including any acceptance thereof) and the terms of this Agreement, the terms of this Agreement will govern. 

  
 9 

 CONFIDENTIAL 
  

 2.5 Cancellation of Accepted Purchase Orders. Each Purchase Order accepted by
Dynavax hereunder shall be non-cancellable except to the extent expressly set forth below: 

(a) The Parties agree that if (i) the export or provision of CpG Material to Purchaser outside of the United States becomes
prohibited under Applicable Law, including, U.S. export control or trade sanctions laws and regulations, and regulations issued by the U.S. Department of Homeland Security’s Federal Emergency Management Agency, (ii) such prohibition lasts
for at least sixty (60) days, and (iii) Dynavax is unable to export or provide CpG Material under a license or other authorization from the relevant Government Authority within such sixty (60) day period, then (x) Purchaser shall
have the right to cancel any accepted Purchase Orders for CpG Material that has not been delivered or authorized for delivery by the relevant Government Authority prior to the end of the sixty (60) day period, (y) Purchaser shall have no
obligation to make payment to Dynavax for CpG Material under any such cancelled Purchase Order that has not been delivered or authorized for delivery by the relevant Government Authority prior to the end of the sixty (60) day period, and
(z) Dynavax shall promptly repay to Purchaser any Advance Payment received from Purchaser for CpG Material under any such cancelled Purchase Order that has not been delivered or authorized for delivery by the relevant Government Authority prior
to the end of the sixty (60) day period. 
 (b) The Parties agree that if the UK Government terminates the Vaccine Supply
Agreement for Product, or reduces or terminates any order which has been placed, after a Purchase Order for CpG Material placed under this Agreement has become binding but before payment by Purchaser of the Final Payment for such CpG Material in
accordance with Section 3.2, (i) Purchaser shall have the right to cancel such Purchase Order (or, in the case of the UK Government’s reduction of an order which has been placed, to reduce such Purchase Order to the extent of such
reduction), and (ii) Purchaser shall not be required to pay the Final Payment for such CpG Material for such cancelled or reduced amounts of CpG Material. For clarity, in such event, Dynavax shall have the right to retain the Advance Payment
for such CpG Material. 
 2.6 Supply. 

(a) Documentation. Dynavax shall establish and maintain any necessary drug master files, standard operating procedures,
protocols, and master Batch records for the manufacture of the CpG Material. Dynavax shall, in connection with each shipment of CpG Material to Purchaser, provide to Purchaser the relevant Certificate of Conformance, Certificate of Analysis, and any
other documentation as may be required in the Quality Agreement with respect to such shipment verifying that each such shipment meets the warranties set forth in Sections 8.1 and 8.2. Without limiting Dynavax’s obligations under the Quality
Agreement, Dynavax shall promptly notify Purchaser after the discovery that any lot of shipped CpG Material, which had previously been approved for release in accordance with the Quality Agreement, fails to comply with its applicable Specifications
or is otherwise not in compliance with Applicable Laws, including providing Purchaser with all details concerning the nature of any such failure to meet Specifications. 

  
 10 

 CONFIDENTIAL 
  

 (b) Release. The Parties will agree to a mechanism in the Quality Agreement
for the shipment of test samples of each Batch of the CpG Material provided to Purchaser for local release testing purposes. 
 2.7
Inspection and Acceptance. 
 (a) Shortages. Purchaser shall notify Dynavax in writing of any shortage in any shipment of
CpG Material within [***] days after receipt. In the event of any verified shortage, Dynavax shall make up the shortage at no cost or expense to Purchaser (beyond the Purchaser’s obligation to make the Final Payment for such shortage amount
following receipt thereof), within [***] Business Days if replacement CpG Material stock is available, or, if it is necessary to produce replacement CpG Material, Dynavax shall promptly start another manufacturing run and shall deliver the
replacement CpG Material to Purchaser within [***] months after the notice of the shortage at no cost or expense to Purchaser (beyond the Purchaser’s obligation to make the Final Payment for such shortage amount following receipt thereof). 

(b) Non-Conforming CpG Material. 

(i) Purchaser shall inspect all shipments of CpG Material promptly upon receipt, and shall notify Dynavax in writing in
reasonable detail if Purchaser is rejecting any CpG Material because it fails to conform to Dynavax’s warranties set forth in Sections 8.2 (a) or 8.2(b) upon delivery, with such notice provided within (A) [***] days after receipt of such
shipment in the case of any nonconformity that is readily observable by visual inspection, or (B) [***] days of learning of such nonconformity where such non-conforming it not readily observable by visual
inspection. All CpG Material not rejected within the applicable [***] period specified in the preceding clause (A) or clause (B), as applicable, will be deemed accepted. 

(ii) If Purchaser notifies Dynavax of any nonconformity of any CpG Material in accordance with Section 2.5(b)(i), Dynavax
shall have the right to inspect the CpG Material in question and Purchaser shall cooperate with Dynavax’s inspection, including providing Dynavax with samples of the CpG Material in question for testing upon request at Dynavax’s expense in
accordance with the process set forth in the Quality Agreement. If Dynavax agrees with such notice of nonconformity, Dynavax shall, at Purchaser’s discretion and Dynavax’s expense, either: (A) replace such CpG Material, at no cost or
expense to Purchaser (beyond the Purchaser’s obligation to make the Final Payment for such replacement CpG Material following receipt thereof), as soon as reasonably practicable after receipt of notification of such nonconformity or
(B) refund any portion of the aggregate Cost per Dose paid to Dynavax for such CpG Material. If it is necessary to produce replacement CpG Material, Dynavax shall promptly start another manufacturing run and shall deliver the replacement CpG
Material to Purchaser within [***] months after the notice of the nonconformity at no cost or expense to Purchaser (beyond the Purchaser’s obligation to make the Final Payment for such replacement CpG Material following receipt thereof). 

(iii) If Dynavax disagrees with Purchaser that the relevant CpG Material did not conform to Dynavax’s warranties set forth in
Section 8.2(a) or 8.2(b), it may require a sample of the allegedly nonconforming CpG Material to be delivered to a mutually acceptable independent testing laboratory for testing. Except in the case of manifest error, the determination

  
 11 

 CONFIDENTIAL 
  

 
of the laboratory as to whether the CpG Material is nonconforming will be final and binding on the Parties with respect to Purchaser’s obligation to accept and pay for the CpG Materials (or,
as applicable, Dynavax’s obligation to provide the applicable remedy specified below). The fees and expenses of such laboratory testing shall be borne entirely by the Party against whom such laboratory’s determination is made. If such
determination is against Purchaser, then such CpG Material shall be deemed accepted by Purchaser for purposes of this Section 2.7(b), and Dynavax shall have no obligation to provide replacement CpG Material. If such determination is against
Dynavax, then Dynavax shall, at Purchaser’s election, either refund the portion of the aggregate Cost per Dose paid by Purchaser for such CpG Material or replace such CpG Material, at no cost or expense to Purchaser (beyond the Purchaser’s
obligation to make the Final Payment for such replacement CpG Material following receipt thereof), as soon as reasonably practicable after replacement CpG Material becomes available. If it is necessary to produce replacement CpG Material, Dynavax
shall promptly start another manufacturing run after the determination against Dynavax and shall deliver the replacement CpG Material to Purchaser within [***] months after such determination at no additional cost or expense to Purchaser (beyond the
Purchaser’s obligation to make the Final Payment for the replacement CpG Material following receipt thereof). 
 (c) Sole
Remedy. [***], the remedies set forth in this Section 2.7 will be Purchaser’s sole and exclusive remedy with respect to nonconforming CpG Material delivered to Purchaser by Dynavax hereunder. This Section 2.7 shall apply to any
replacement CpG Material supplied by Dynavax. 
 (d) Damage after Delivery. Purchaser shall bear the risk of damage to the
CpG Material after delivery to Purchaser pursuant to Section 2.4(a). If the CpG Material is damaged after delivery, and Purchaser intends to order replacement CpG Material, Purchaser shall promptly notify Dynavax of the damage and any orders
for replacement CpG Material, and Dynavax shall use commercially reasonable efforts to deliver the requested replacement CpG Material. To the extent such order is accepted by Dynavax, Dynavax shall deliver the accepted quantity of such replacement
CpG Material, as soon as reasonably practicable after replacement CpG Material becomes available. 
 2.8 Allocation in the Event of
Product Shortages. 
 The following provisions of this Section 2.8 shall not limit Dynavax’s obligations under this Agreement
and in particular its obligations under Sections 2.2, 2.3 and 2.4 and its obligations to indemnify the Purchaser set out in Section 9.1: 

(a) If at any time, Dynavax determines that it will not be able to deliver the quantities of CpG Material specified in any
Purchase Order placed in accordance with this Agreement on the applicable delivery date, or Dynavax is made aware of any future anticipated shortages, then Dynavax shall immediately notify Purchaser of such determination. Such notification shall
include the reasons for and the expected duration of Dynavax’s anticipated inability to deliver such quantities of CpG Material and steps being taken to immediately commence providing the required quantities of CpG Material. Promptly
thereafter, the Parties shall discuss in good faith the matters set forth in such notification and begin good faith negotiations with respect to an alternative delivery schedule or alternative sourcing for the CpG Material. 

  
 12 

 CONFIDENTIAL 
  

 (b) Subject to paragraph (c) below, if Dynavax is
unable to supply, with respect to a Calendar Quarter, the total quantity of CpG Material ordered by Purchaser pursuant to Section 2.2 or 2.3 for delivery in such Calendar Quarter, plus the total quantity of CpG Material required by Dynavax or
its Affiliates or other purchasers for their respective use in such Calendar Quarter (such event, a “Shortfall”), the following shall apply: 

(i) In the event of a Shortfall, the available CpG Material in each Calendar Quarter in which a
Shortfall occurs shall be allocated [***] on the basis of [***] for such Calendar Quarter. 
 (ii)
The allocation rules set forth in this Section 2.8 (b) shall restart for each Calendar Quarter, without any carryover of a Shortfall realized by either Purchaser or Dynavax in the prior Calendar Quarter. 

(c) The provisions of paragraph (b) above shall be subject to the following in respect of
Purchase Orders submitted to Dynavax in accordance with Section 2.2: 
 (i) Dynavax shall in
all circumstances take commercially reasonable endeavours to ensure continuity and timeliness of supply of Purchaser’s requirements as set forth in such Purchase Orders; 

(ii) Dynavax shall notify the Purchaser immediately if it fails, or expects to fail to deliver any
amount of CpG Material in full and on time to the Purchaser; 
 (iii) if Dynavax fails to deliver
CpG Material to the Purchaser on time and in full and this results in [***], or [***], [***] the relevant order (but not of any other order) shall [***]; 

(iv) during any period in which any such CpG Material is awaiting delivery Dynavax shall [***], and
Dynavax shall provide weekly update reports on such delay, the causes of such delay and remedial action being taken. 
 2.9
Supply Contacts. Each Party shall designate one (1) qualified and experienced supply chain professional to serve as that Party’s primary supply contact regarding the supply of CpG Material pursuant to this
Agreement (“Supply Contacts”). Each Party may replace its Supply Contact with an alternative representative at any time with prior written notice to the other Party. Supply Contacts shall be responsible for facilitating information
exchange and discussion between the Parties regarding the supply of CpG Material under this Agreement. Each Party shall bear its own costs of its Supply Contact. 

2.10 Use of CMOs. Dynavax will have the right to use CMOs to supply the CpG Material ordered by
Purchaser, [***], provided that: (a) Dynavax shall be responsible for the compliance of any CMOs with this Agreement; (b) Dynavax remains fully and primarily responsible to Purchaser for the performance of, and acts and omissions of, such
CMOs, as if committed by Dynavax; and (c) in no event shall Purchaser have any liability to any such CMO for any failure of Dynavax to perform under its agreement with such CMO, including any failure to pay any amounts due to such CMO (it being
understood, however, that Purchaser may have liability to Dynavax for any failure to pay any undisputed amounts due to Dynavax hereunder that results in Dynavax’s inability to pay such CMO). [***]. 

  
 13 

 CONFIDENTIAL 
  

 ARTICLE 3 

FINANCIALS 
 3.1
Price. Subject to the remainder of this Article 3, all CpG Material supplied by Dynavax to Purchaser under this Agreement that is manufactured in 2020 and 2021 shall be at a price equal to the Cost per Dose of such
CpG Material as set forth in Exhibit C. Thereafter the Cost per Dose shall be subject to adjustment, [***], and the Parties shall update Exhibit C accordingly. The Cost per Dose is exclusive of (a) any customs duties or taxes
imposed with respect to the export of the product and (b) all shipping and associated costs and all taxes, duties, or other fees of whatever nature imposed with respect to CpG Material supplied hereunder by or under the authority of any
Government Authority (including any import duty to the UK), all of which Purchaser agrees to pay in addition to the Cost per Dose. For clarity, Dynavax will be solely responsible for payment of taxes on Dynavax’s income. The Parties hereby
agree that the Cost per Dose set forth in Exhibit C as of the Effective Date is valid only for CpG Material that is intended for use in, and is used in, the manufacture of Products for use in the Field during the Pandemic. If Purchaser
desires to use any of the CpG Material supplied under this Agreement in any Product for use after the Pandemic, any such use shall be subject to [***] Valneva Austria’s SARS-COV2 Vaccine Supply Agreement with the Secretary of State for
Business, Energy and Industrial Strategy, on behalf of the UK Crown (the “Vaccine Supply Agreement”), and where Purchaser has already paid the Final Payment for such shipment of CpG Material, Purchaser would be obligated to pay
Dynavax [***]. 
 3.2 Invoice and Payment. Without prejudice to the obligations to pay Reservation
Fees as applicable. in respect of the CpG Material ordered in any accepted Purchase Order, Dynavax will invoice Purchaser for [***] of the aggregate Cost per Dose of such CpG Material (the “Advance Payment”) upon Dynavax’s
acceptance of such Purchase Order (provided always that the amount of any Reservation Fee paid in respect of such amount of CpG Material shall be deemed a prepayment against and deducted from such amount of the aggregate Cost per Dose of such CpG
Material) and for [***] of the aggregate Cost per Dose of such CpG Material (the “Final Payment”) upon delivery of such CpG Material in accordance with Section 2.4(a). Purchaser shall pay each invoice, in U.S. Dollars, within
[***] days after receipt of such invoice by wire transfer of immediately available funds into an account designated by Dynavax. If Purchaser disputes any invoiced amount hereunder (or a portion thereof), Purchaser shall timely pay any undisputed
portion of the invoiced amount in accordance with the preceding sentence and shall notify Dynavax in writing of the disputed amount, including the basis on which Purchaser disputes such amount, within [***] days after receipt of the invoice. 

3.3 Late Payment. If any undisputed payment due under this Agreement is not paid when due in
accordance with the applicable provisions of this Agreement, such payment shall accrue interest from the date due at the annual interest rate of [***] provided, however, that in no event shall such rate exceed the maximum legal annual
interest rate. The payment of such interest shall not limit Dynavax from exercising any other rights it may have as a consequence of the lateness of any payment. 

  
 14 

 CONFIDENTIAL 
  

 3.4 Tax. Purchaser shall pay any and all taxes
(other than taxes based on Dynavax’s income), duties, assessments, and other charges and expenses imposed by any Government Authority on the sale, supply, transfer, export or import of CpG Material hereunder. If a withholding or deduction
obligation occurs, then the sum payable by Purchaser in respect of which such deduction or withholding is required to be made shall be increased to the extent necessary to ensure that Dynavax receives a sum equal to the sum which it would have
received had no such withholding or deduction occurred. 
 ARTICLE 4 

REGULATORY; QUALITY 

4.1 Quality Agreement. As soon as reasonably practicable after the Effective Date, but no later than
ninety (90) days thereafter, the Parties shall negotiate in good faith and agree to the terms and conditions of a quality agreement (the “Quality Agreement”), which shall be consistent in all material respects with
Dynavax’s quality agreement with its CMO, setting forth the respective responsibilities of Parties in relation to quality as required for compliance with Applicable Laws, including GMP, and including provisions (a) [***] and (b) [***]. The
Quality Agreement is hereby incorporated herein by reference. To the extent that the terms of this Agreement and those of the Quality Agreement are in conflict, the terms of this Agreement shall control except with respect to quality issues, which
shall be governed by the Quality Agreement. Each Party agrees to comply, and to cause its Affiliates and, in the case of Dynavax, its CMOs, to comply, with such Party’s obligations under the Quality Agreement. 

4.2 GMP, Quality Assurance, and Other Audits. During normal business hours and with reasonable
advance notice, Purchaser shall have the right to conduct GMP, quality assurance, and other audits of any location relating to the supply of CpG Material hereunder, including at Dynavax’s CMO, as further set forth in the Quality Agreement, and
Dynavax shall and shall cause its Affiliates and any such Third Party, including Dynavax’s CMO, to cooperate with Purchaser, its Affiliates, and their representatives in any such audit or inspection as further set forth in the Quality
Agreement. Purchaser shall be responsible for the reasonable and documented cost of any audit it conducts, including any reasonable and documented amounts charged by Dynavax’s CMO in connection therewith. 

4.3 Regulatory Inspections. Dynavax shall cooperate and cause its Affiliates and CMO to cooperate
with any inspection of the Facility by any Government Authority or Regulatory Authority, including in connection with the Regulatory Approval process for the Product. Dynavax shall promptly notify Purchaser in writing if any Regulatory Authority
notifies Dynavax that it intends to or (if no notice was provided, that does) visit the Facility for the purpose of reviewing the manufacture of CpG Material. To the extent practicable under the circumstances and not prohibited by such Regulatory
Authority, Dynavax shall permit a reasonable number of Purchaser’s representatives to be present on site for such visit. Dynavax shall promptly provide Purchaser with a copy of (i) any reports or other correspondence issued by such
Regulatory Authority following such visit, and (ii) any material reports, comments, responses or other correspondence prepared by or on behalf of Dynavax, including its CMO, from or to (as applicable) any Regulatory Authority which relates
specifically to or would reasonably be expected to affect the Products, including any comments, responses or notices received from the Regulatory Authority with respect thereto, in each of (i) and (ii), redacted as appropriate to protect any

  
 15 

 CONFIDENTIAL 
  

 
confidential information of Dynavax’s other customers. Purchaser acknowledges that it may not direct the manner in which Dynavax fulfills its obligations to permit such inspection by and to
communicate with Regulatory Authorities; provided that Dynavax does so in accordance with Applicable Laws. 
 4.4
Pharmacovigilance Agreement. As soon as reasonably practicable after the Effective Date, and in any event, prior to the use of the Product in any human clinical trial, the Parties shall enter into a pharmacovigilance
agreement setting forth the pharmacovigilance responsibilities of the Parties with respect to the CpG Material (the “Pharmacovigilance Agreement”). Each Party agrees to comply, and to cause its Affiliates and, in the case of
Purchaser, Purchaser’s licensees of the Product, to comply, with such Party’s obligations under the Pharmacovigilance Agreement. 

4.5 Required Licenses. 

(a) For CpG Material. Dynavax shall, at all times during the Term, have and maintain all of the
licences, permissions, authorizations, consents, and permits that it needs to carry out its obligations under this Agreement in compliance with Applicable Laws, including, if necessary, a drug master file in respect of the CpG Material (the
“DMF”). Upon request, Dynavax shall provide, or cause its CMO to provide, to relevant Regulatory Authorities letters of authorization or other written statements permitting such Regulatory Authorities to refer to information in the
DMF in support of Purchaser’s CTAs or Regulatory Approvals for Products, without direct disclosure to Purchaser of such information. Unless required by Applicable Laws, in no event shall Dynavax or its CMO be obligated to provide the DMF or any
information contained therein directly to Purchaser or its Affiliates. Upon Purchaser’s request, Dynavax will provide directly to relevant Regulatory Authorities such other data and documentation regarding the CpG Materials or the manufacture
thereof as are reasonably required for Purchaser to apply for and maintain CTAs and Regulatory Approvals for use of the CpG Materials in the Products, provided that, unless required by Applicable Laws, Dynavax nor its CMO shall have any obligation
to provide or disclose any such data or documentation to Purchaser. Subject to the foregoing limitations on Dynavax’s obligations, Dynavax shall also, upon Purchaser’s request, reasonably assist Purchaser and its designees in preparing and
updating any submissions or other documents required by any Regulatory Authority for approval of the Products, and Purchaser shall compensate Dynavax for providing such assistance at a reasonable hourly rate to be mutually agreed by the Parties.

 (b) For Products. For the avoidance of doubt, Purchaser shall be solely responsible for
obtaining and maintaining all licenses, permissions, authorizations, consents, and permits necessary for the research, development, manufacture (excluding manufacture of the CpG Material), use, marketing, promotion, distribution, handling, storage,
sale, or other disposition of the Vaccine and Products, and for complying with all Applicable Laws in connection with carrying out the foregoing activities. 

  
 16 

 CONFIDENTIAL 
  

 ARTICLE 5 

USE OF CPG MATERIAL 

5.1 License Grant. Subject to the terms of this Agreement, including Section 5.2, Dynavax
hereby grants to Purchaser a worldwide, fully-paid up, royalty-free, non-exclusive, non- transferable (except in connection with a permitted assignment of this Agreement
in accordance with Section 11.6), limited license, with the right to grant sublicenses, under the Dynavax Technology solely to develop, make, have made, use, sell, have sold, offer for sale, import and otherwise commercially exploit Products in
the Field; provided, however, that the foregoing license to make and have made Products is limited to the right to make or have made Products using the CpG Material supplied by Dynavax pursuant to this Agreement, and specifically excludes any
license or other right to make or have made the CpG Adjuvant or CpG Material. The license granted to Purchaser in this Section 5.1 includes the right to sublicense (through multiple tiers) to Purchaser’s Affiliates and to Purchaser’s
or Purchaser’s Affiliates’ licensees or distributors of Products and any other companies that work with Purchaser or Affiliate in connection with the manufacture, supply, and other commercialization of the Products and Purchaser shall be
responsible for the compliance of any sublicensees with this Agreement. Purchaser shall not have any other right to grant sublicenses under the license granted to Purchaser in this Section 5.1; provided, however, that Purchaser may
contract with Third Party CMOs for the manufacture, on Purchaser’s behalf, of Products using the CpG Material supplied under this Agreement, and such contracting shall not be considered a sublicense. The foregoing license shall not be construed
to obligate Dynavax to disclose or transfer to Purchaser any Dynavax Technology. 
 5.2 [***]. 

5.3 No Implied License. Except as set forth in this Agreement, neither Party shall acquire any
license or other intellectual property interest, by implication or otherwise, under or to any Patents or Know-How owned or controlled by the other Party. 

ARTICLE 6 
 INTELLECTUAL
PROPERTY 
 6.1 Ownership of
CpG Adjuvant, Vaccine and Vaccine Formulation. Purchaser and Valneva Austria
acknowledge that the CpG Adjuvant is proprietary to Dynavax, that Dynavax is and shall at all times remain the sole and exclusive owner of, and shall not be restricted in any way from taking any steps to protect, any and all intellectual property
rights of any nature whatsoever and whenever and however arising in and to the CpG Adjuvant, and that neither Purchaser nor Valneva Austria shall not obtain any right, ownership interest, or, except as expressly set forth in Section 5.1,
license in or to the CpG Material as a result of its purchase, receipt, or use of the CpG Material under this Agreement. Dynavax acknowledges that the Vaccine and Vaccine Formulation are proprietary to Purchaser or its Affiliate, that Purchaser or
its Affiliate is and shall at all times remain the sole and exclusive owner of, and shall not be restricted in any way from taking any steps to protect, any and all intellectual property rights of any nature whatsoever and whenever and however
arising in and to the Vaccine and Vaccine Formulation, and that Dynavax shall not obtain any right, ownership interest, or license in or to the Vaccine and Vaccine Formulation as a result of the inclusion by Purchaser or Valneva Austria of the CPG
Material in the Product or otherwise. 

  
 17 

 CONFIDENTIAL 
  

 6.2 Ownership of Foreground IP related to CpG Adjuvant,
Vaccine, Vaccine Formulation. Dynavax shall own any invention, discovery and know how, as well as any patent or other intellectual property rights thereunder that solely relate to, is an improvement or modification of, or is a new method of use
of solely the CpG Adjuvant arising under the Collaboration Agreements (“Dynavax Foreground IP”). Purchaser shall own any invention, discovery and know how, as well as any patent or other intellectual property rights thereunder that
solely relate to, is an improvement or modification of, or is a new method of use of solely Vaccine or Vaccine Formulation arising under the Collaboration Agreements (“Valneva Foreground IP”). 

6.3 Ownership of Foreground Patents related to Product. Dynavax and Valneva Austria shall jointly
own all Patents arising under the Collaboration Agreements, solely where such Patents relate [***] (“Joint Patents”). All other intellectual property arising under the Collaboration Agreements other than the Dynavax Foreground IP,
the Valneva Foreground IP, and Joint Patents, shall [***]. 
 6.4 License to Dynavax. Valneva
Austria hereby grants Dynavax (a) [***] license under the Joint Patents to make, use, develop, sell, and commercialize, any vaccine other than the Product or a Biosimilar Version of the Product, and (b) [***] license under the Joint Patents to make,
use, develop, sell, and otherwise commercialize the CpG Adjuvant [***]. 
 6.5 License to Purchaser.
In addition to the licenses granted under Section 5.1, Dynavax hereby grants Purchaser (a) [***] license under the Joint Patents to make, use, develop, sell, and otherwise commercialize, any vaccine, and (b) [***] license under the Joint
Patents to make, use, develop, sell, and otherwise commercialize the Product or Biosimilar Versions thereof. 
 6.6
Prosecution, Maintenance of Joint Patents: Dynavax, Valneva Austria and Purchaser agree that the inventorship shall be determined in accordance with U.S. patents laws. Valneva Austria shall have the sole right to
file, prosecute and maintain any patent rights with regard to Joint Patents, at Valneva Austria’s sole cost. At Valneva Austria’s request and cost, Dynavax shall cooperate and assist Purchaser in the preparation, prosecution and
maintenance of such Joint Patents. Valneva Austria shall keep Dynavax informed on the status of the preparation, filing, prosecution and maintenance of all Joint Patents. Further, Valneva Austria will (i) allow Dynavax a reasonable opportunity
and reasonable time to review and provide comment to Valneva Austria’s counsel regarding relevant substantive communications to Valneva Austria’s drafts of any responses or other proposed substantive filings by Valneva Austria before any
applicable filings are submitted to any relevant patent office (or governmental authority) in a major market and (ii) reflect any reasonable and timely comments offered by Dynavax in any final filings submitted by Valneva Austria to any
relevant patent office (or governmental authority) in a major markets unless Valneva Austria believes doing so may delay filing issuance, maintenance or otherwise compromise or adversely affect patent coverage for the Product. 

6.7 Enforcement and Defense of Joint Patents: Valneva Austria and its Affiliates and sublicensees
shall have the exclusive right to enforce and defend those Joint Patents against Third Parties which infringe the subject matter of any of the Joint Patents solely related to the Product or a Biosimilar Version of the Product (but not any other
vaccine). Dynavax shall have the exclusive right to enforce and defend those Joint Patents against Third Parties which infringe the subject matter of any Joint Patents solely related to the CpG Adjuvant [***]. For the avoidance of doubt,

  
 18 

 CONFIDENTIAL 
  

 
neither Party shall concede the invalidity of the Joint Patents in any settlement discussions with Third Parties. Valneva Austria and Dynavax shall cooperate, at the cost of the requestor, in any
enforcement or defense actions of the Joint Patents, including being joined as a party, if required under the relevant Applicable Law. In the event that a Party wishes to enforce and/or defend against any Third Party any Joint Patents that do not
(i) solely relate to the Product or a Biosimilar Version of the Product, or (ii) solely relate to the CpG Adjuvant [***], the Parties shall in good faith discuss and agree the basis upon which such enforcement may proceed. 

6.8 Collaboration Agreements. This Article 6 supersedes the entirety of Sections 6.2 and 6.4 in that
certain Clinical Collaboration Agreement dated July 31, 2020 between Dynavax and Valneva Austria, and the entirety of Section 3 of that certain Collaboration Agreement dated April 15, 2020, between Dynavax and Valneva Austria, as
amended by Amendment No. 1 dated July 29, 2020. 
 ARTICLE 7 

CONFIDENTIALITY 

7.1 Confidentiality. At all times during the Term and for a period of [***] years thereafter, each
Party shall, and shall cause its Affiliates and its and their respective officers, directors, employees, consultants, contractors, and agents to, keep confidential and not publish or otherwise disclose to a Third Party and not use, directly or
indirectly, for any purpose, any Confidential Information furnished or otherwise made known to it, directly or indirectly, by the other Party, except to the extent such disclosure or use is expressly permitted by the terms of this Agreement.
Notwithstanding the foregoing, the confidentiality and non-use obligations under this Section 7.1 shall not include any information that: 

(a) has been published by a Third Party or otherwise is or hereafter becomes part of the public
domain by public use, publication, general knowledge, or the like through no wrongful act, fault, or negligence on the part of the Receiving Party; 

(b) was in the Receiving Party’s possession (or that of any of its Affiliates) prior to
disclosure by the Disclosing Party without any obligation of confidentiality with respect to such information, as evidenced by the Receiving Party’s records or other competent proof; 

(c) is subsequently received by the Receiving Party (or that of any of its Affiliates) from a Third
Party without restriction and without the Receiving Party’s knowledge of breach of any agreement between such Third Party and the Disclosing Party; 

(d) is made available to Third Parties by the Disclosing Party without restriction on disclosure to the
Receiving Party’s knowledge; or 
 (e) has been independently developed by the Receiving
Party (or that of any of its Affiliates) without use of, or access to, the Disclosing Party’s Confidential Information as evidenced by the Receiving Party’s records or other competent proof. 

Specific aspects or details of Confidential Information shall not be deemed to be within the public domain or in the possession of the
Receiving Party merely because the Confidential 

  
 19 

 CONFIDENTIAL 
  

 
Information is embraced by more general information in the public domain or in the possession of the receiving Party. Further, any combination of Confidential Information shall not be considered
in the public domain or in the possession of the Receiving Party merely because individual elements of such Confidential Information are in the public domain or in the possession of the Receiving Party unless the combination and its principles are
in the public domain or in the possession of the Receiving Party. 
 7.2 Permitted Disclosures.
The Receiving Party may disclose the existence or terms of this Agreement or Confidential Information of the Disclosing Party as expressly permitted by this Agreement or to the extent such disclosure is reasonably necessary in the following
instances: 
 (a) obtaining and maintaining CTAs and Regulatory Approvals of CpG Adjuvant (in the
case of Dynavax as the Receiving Party) and Products (in the case of Purchaser as the Receiving Party); 
 (b)
complying with valid court orders or Applicable Laws, or the rules of any securities exchange on which a Party’s securities are listed or the requirements of any Regulatory Authority or Government Authority; 

(c) in the case of the Purchaser, in responding to requests for information from the UK Government
requiring such disclosure; 
 (d) disclosure to its and its Affiliates’ employees,
consultants, contractors, and agents, in each case on a need-to-know basis in connection with development or manufacture of the CpG Material (in the case of Dynavax) or
the development, manufacture, or commercialization of any Product (in the case of Purchaser), in each case in accordance with the terms of this Agreement and under written obligations of confidentiality and
non-use at least substantially similar to those herein; and 
 (e)
disclosure to actual and bona fide potential investors, acquirors, and other financial partners for the purpose of evaluating or carrying out an actual or potential investment or acquisition, in each case under
written obligations of confidentiality and non-use at least as stringent as those herein; provided that the disclosing Party limits such disclosure to the maximum extent possible and redacts the financial
terms and other provisions of this Agreement that are not reasonably required to be disclosed in connection with such potential investment or acquisition. 

Notwithstanding the foregoing, in the event a Party is required to make a disclosure of the other Party’s Confidential Information
pursuant to Section 7.2(b) or Section 7.2(c), it will, except where impermissible, give reasonable advance notice to the other Party of such required disclosure and comply with all reasonable requests of the Disclosing Party with respect
to maintaining confidence of such Confidential Information and in any event shall use at least the same diligent efforts to secure confidential treatment of such Confidential Information as such Party would use to protect its own confidential
information of a similar nature, but in no event less than reasonable efforts. 
 7.3 Use of Name.
Except as expressly provided herein, neither Party shall use the name, logo, or trademark of the other Party or any of its Affiliates (or any abbreviation or 

  
 20 

 CONFIDENTIAL 
  

 
adaptation thereof) in any publication, press release, marketing and promotional material, or other form of publicity without the prior written approval of such other Party in each instance,
which approval shall not be unreasonably withheld or delayed. The restrictions imposed by this Section 7.3 shall not prohibit either Party from making any disclosure identifying the other Party that, in the opinion of the Disclosing
Party’s counsel, is required by Applicable Law. 
 7.4 Return of Confidential Information.
Upon the earlier of expiration or termination of this Agreement for any reason, each Party shall promptly return to the other Party, or delete or destroy, in each such Party’s discretion, all records and materials in such Party’s
possession or control containing Confidential Information of the other Party; provided that the other Party shall be permitted to retain one (1) copy of such Confidential Information for the sole purpose of performing any continuing obligations
under this Agreement, as required by Applicable Law, or for legal archival purposes, which copy shall remain subject to the non-use and non-disclosure provisions
contained herein. 
 ARTICLE 8 

REPRESENTATIONS AND WARRANTIES 

8.1 Mutual Representations, Warranties, and Covenants. 

(a) Authorizations. Each Party represents and warrants to the other Party that, as of the Effective
Date: (i) it is duly organized and validly existing under the laws of its jurisdiction of incorporation or formation, and has full corporate or other power and authority to enter into this Agreement and to carry out the provisions hereof,
(ii) it is duly authorized to execute and deliver this Agreement and to perform its obligations hereunder, and the person or persons executing this Agreement on its behalf has been duly authorized to do so by all requisite corporate or
partnership action, and (iii) this Agreement is legally binding upon it, enforceable in accordance with its terms, and does not conflict with any agreement, instrument, or understanding, oral or written, to which it is a party or by which it
may be bound, nor violate any material law or regulation of any court, governmental body, or administrative or other agency having jurisdiction over it. 

(b) Debarment. Dynavax represents, warrants, and covenants to Purchaser that none of it, its
Affiliates, or, to its knowledge based on representations, warranties and covenants made by its CMOs, its CMOs, is debarred or disqualified under the U.S. Federal Food, Drug and Cosmetic Act, or comparable laws in any country or jurisdiction other
than the U.S., (nor is aware of any pending or potential actions that would give rise to such ineligibility) and it and its Affiliates does not, and will not during the Term, employ or use the services of any Person who is debarred or disqualified,
in connection with activities relating to the CpG Material or any Product. In the event that Dynavax becomes aware of the debarment or disqualification or threatened debarment or disqualification of any person providing services to Dynavax,
including Dynavax itself or its Affiliates, that directly or indirectly relate to activities contemplated by this Agreement, Dynavax shall immediately notify Purchaser in writing and shall cease employing, contracting with, or retaining any such
Person to perform any such services. 
 (c) CMOs. Dynavax represents and warrants to Purchaser
that (i) each Facility at which CpG Material is manufactured, tested, stored, packaged, labeled or supplied, is operated 

  
 21 

 CONFIDENTIAL 
  

 
in compliance with Applicable Laws, including GMP and is registered with the applicable Regulatory Authority; and (ii) its agreements with its CMOs, including any quality or
pharmacovigilance agreements, contain terms that are customary in biopharmaceutical industry and required to ensure that the CpG Material is manufactured, tested, stored, packaged, labeled, and supplied in compliance with Applicable Laws, including
GMP. 
 8.2 Product Warranties. Dynavax represents and warrants to Purchaser that: 

(a) all CpG Material supplied to Purchaser pursuant to this Agreement will be manufactured in compliance
with Applicable Laws relevant to the manufacture of the CpG Material at the Facility, including GMP; 
 (b)
all CpG Material supplied to Purchaser pursuant to this Agreement, at the time of delivery of such CpG Material to Purchaser pursuant to Section 2.4(a), will comply with the Specifications; and 

(c) all CpG Material supplied to Purchaser pursuant to this Agreement will, at the time of delivery
of such CpG Material to Purchaser pursuant to Section 2.4(a), be free and clear of any liens, security interests, or other encumbrances. 

8.3 Mutual Covenants. Each Party hereby covenants to the other Party that, in connection with the performance of its activities
under this Agreement: 
 (a) neither such Party nor any of its Affiliates will, (or any of their
respective employees and consultants (including CMOs) directly or indirectly through Affiliates or Third Parties, pay, promise, or offer to pay, or authorize the payment of, any money or give any promise or offer to give, or authorize the giving of
anything of value to a public official or entity or other Person for purpose of obtaining or retaining business for or with, or directing business to, any Person, including such Party and its Affiliates, nor will such Party or any of its Affiliates
(or any of their respective employees and consultants (including CMOs) directly or indirectly promise, offer, or provide any corrupt payment, gratuity, emolument, bribe, kickback, illicit gift, or hospitality or other illegal or unethical benefit to
a public official or entity or any other Person; 
 (b) neither such Party nor any of its Affiliates (or
any of their respective employees and consultants or CMOs), in connection with the exercise of such Party’s rights or performance of such Party’s obligations under this Agreement, shall cause the other Party to be in violation of
Anti-Corruption Laws or Export Control Laws; 
 (c) such Party shall immediately notify the other
Party if such Party has any information that there is or is likely to be a violation of Anti-Corruption Laws or Export Control Laws in connection with the exercise of such Party’s rights or performance of
such Party’s obligations under this Agreement; and 
 (d) each Party shall undertake due diligence
activities appropriate to its activities under this Agreement in accordance with applicable Anti-Corruption Laws and related guidance, including guidance issued by the U.S. Department of Justice Criminal
Division (entitled “Evaluation of Corporate Compliance Programs”) concerning the FCPA, and issued by the U.K. 

  
 22 

 CONFIDENTIAL 
  

 
Ministry of Justice concerning the UK Bribery Act 2010, such activities to include the conduct of appropriate due diligence in relation to Third Party contractors, and shall to the extent
permitted by Applicable Law, reasonably collaborate with the other Party to ensure such compliance. 
 8.4
Disclaimers. EXCEPT AS EXPRESSLY STATED IN THIS AGREEMENT, NEITHER PARTY MAKES ANY REPRESENTATIONS OR EXTENDS ANY WARRANTIES OF ANY KIND, EITHER EXPRESS OR IMPLIED, AND EACH PARTY EXPRESSLY DISCLAIMS ANY AND ALL
WARRANTIES OF ANY KIND, EXPRESS OR IMPLIED, INCLUDING THE WARRANTIES OF DESIGN, MERCHANTABILITY, FITNESS FOR A PARTICULAR PURPOSE, NON-INFRINGEMENT OF THE INTELLECTUAL PROPERTY RIGHTS OF THIRD PARTIES, OR
ARISING FROM A COURSE OF DEALING, USAGE. 
 ARTICLE 9 

INDEMNIFICATION 

9.1 Indemnification by Dynavax. Dynavax shall defend, indemnify, and hold harmless Purchaser and its
Affiliates and their respective directors, officers, employees, and agents (each, a “Purchaser Indemnitee”) from and against any and all losses, damages, liabilities, and expenses (including reasonable attorneys’ fees and
expenses) (collectively, “Losses”) incurred by the Purchaser Indemnitees as a result of any claim, demand, action, or other proceeding by a Third Party (collectively, “Claims”) to the extent caused by: (a) the
breach by any Dynavax Indemnitee (including of its CMOs) of any warranty, representation, covenant, or agreement made by Dynavax in this Agreement; or (b) the negligence, gross negligence or willful misconduct of any Dynavax Indemnitee or its
CMOs; or (c) the CpG Material provided under this Agreement, including claims that the manufacture, use, supply, import or export of the CpG Materials infringes or misappropriates a Third Party’s intellectual property rights; except, in
each case ((a) through (c)), to the extent such Losses or Claims result from an event for which Purchaser has an obligation to indemnify Dynavax under Section 9.2. 

9.2 Indemnification by Purchaser. Purchaser shall defend, indemnify, and hold harmless Dynavax and
its Affiliates and their respective directors, officers, employees, and agents (each, a “Dynavax Indemnitee”) from and against any and all Losses incurred by the Dynavax Indemnitees as a result of any Claim to the extent caused by:
(a) the breach by any Purchaser Indemnitee of any warranty, representation, covenant, or agreement made by Purchaser in this Agreement, (b) the negligence, gross negligence or willful misconduct of any Purchaser Indemnitee, or (c) the
disposition by or on behalf of Purchaser of any Product manufactured with CpG Materials under this Agreement, including claims that the manufacture, use, supply, import or export of Product (excluding the CpG Materials), infringes or misappropriates
a Third Party’s intellectual property rights; except, in each case ((a)-(c)), to the extent such Losses or Claims result from an event for which Dynavax has an obligation to indemnify Purchaser under Section 9.1. 

9.3 Indemnification Procedures. A Party that intends to claim indemnification under this Article 9
(the “Indemnitee”) shall promptly notify the indemnifying Party (the “Indemnitor”) in writing of the Claim in respect of which the Indemnitee intends to claim such indemnification, and subject to the remainder of
this Section 9.3, the Indemnitor shall have sole control of the defense or settlement thereof at its own expense. The failure to deliver written notice to the Indemnitor within a reasonable time after the commencement of any action with respect
to a Claim 

  
 23 

 CONFIDENTIAL 
  

 
shall only relieve the Indemnitor of its indemnification obligations under this Article 9 if and to the extent the Indemnitor is actually prejudiced thereby. The Indemnitee may participate in the
Indemnitor’s defense of and settlement negotiations for any Claim with counsel of the Indemnitee’s own choice (but in that case at the Indemnitee’s cost and expense). The Indemnitee shall not settle any Claim for which it seeks
indemnification hereunder without the consent of the Indemnitor, which consent shall not be unreasonably withheld, conditioned, or delayed. The Indemnitor shall not settle any Claim which imposes any liability or obligation on the Indemnitee (unless
the settlement involves only the payment of money), involves any admission of wrongdoing on the part of the Indemnitee, or does not include a release of all claims against the Indemnitee, without the prior written consent of the Indemnitee, which
consent shall not to be unreasonably withheld, conditioned, or delayed. The Indemnitee shall reasonably cooperate with the Indemnitor and its legal representatives in the investigation of any action with respect to a Claim covered by this
indemnification at the Indemnitor’s expense. 
 9.4 Insurance. Each Party shall maintain
commercial general liability insurance and product liability and other appropriate insurance, at its own expense, in an amount consistent with sound business practice and reasonable in light of its obligations under this Agreement. Each Party shall
maintain such insurance for the period commencing promptly after the Effective Date until [***] years after the Term. Each Party shall provide evidence of such coverage to the other Party upon request, including a certificate of insurance (if
applicable). It is understood that such insurance shall not be construed to create any limit of either Party’s obligations or liabilities with respect to its indemnification obligations under this Agreement. 

9.5 Limitation of Liability. 

(a) EXCEPT AS PROVIDED UNDER SECTION 9.5(b), (I) NEITHER PARTY SHALL BE LIABLE TO THE OTHER FOR ANY
SPECIAL, CONSEQUENTIAL, INCIDENTAL OR PUNITIVE DAMAGES, OR LOST PROFITS, ARISING FROM OR RELATING TO THIS AGREEMENT, THE CPG MATERIALS, OR THE PRODUCT, INCLUDING ANY BREACH OF THIS AGREEMENT, REGARDLESS OF ANY NOTICE OF THE POSSIBILITY OF SUCH
DAMAGES AND (II) EACH PARTY’S MAXIMUM LIABILITY FOR DAMAGES RELATED TO THIS AGREEMENT, THE CPG MATERIALS OR PRODUCT, REGARDLESS OF THE CAUSE OF ACTION, WILL NOT EXCEED [***]. 

(b) NOTWITHSTANDING THE FOREGOING, NOTHING IN THIS AGREEMENT IS INTENDED TO OR SHALL LIMIT OR
RESTRICT AND THE LIMITATIONS UNDER SECTION 9.5(a) SHALL NOT APPLY WITH RESPECT TO (I) ANY LOSSES OR CLAIMS SUBJECT TO EITHER PARTY’S INDEMNIFICATION RIGHTS OR OBLIGATIONS UNDER SECTIONS 9.1 OR 9.2, (II) DAMAGES AVAILABLE FOR A PARTY’S
BREACH OF CONFIDENTIALITY OBLIGATIONS IN ARTICLE 7, OR (III) A PARTY’S RIGHT TO RECOVER DAMAGES FOR FRAUD BY THE OTHER PARTY. 

  
 24 

 CONFIDENTIAL 
  

 ARTICLE 10 

TERM AND TERMINATION 

10.1 Term. 

(a) The provisions of this Section 10.1 and of Section 11.2 shall be legally binding immediately as this Agreement has been
signed by both Parties. All other provisions of this Agreement shall be effective and legally binding upon the Parties upon the later of: 

(i) the execution of the Vaccine Supply Agreement by both the Valneva Austria and the UK Crown (prompt notice of which will be
provided by Purchaser to Dynavax); and 
 (ii) one minute after the end of trading on NASDAQ on Friday 11 September 2020
(the “Effective Date”). If the Vaccine Supply Agreement is not executed by the Valneva Austria and the UK Crown by 11.59 pm UK time on Sunday 13 September 2020, this Agreement will be null and void ab initio and will
have no effect whatsoever. 
 (b) This Agreement will commence on the Effective Date and will continue through December 31, 2025 or
until earlier terminated by the Parties pursuant to Section 10.2 (the “Initial Term”). After the Initial Term, this Agreement shall automatically renew each year thereafter for a period of one (1) year (each, a
“Renewal Term” and all Renewal Terms together with the Initial Term, the “Term”), unless either Party notifies the other Party in writing twelve (12) months prior to the renewal date that the notifying Party
does not wish to renew the Agreement. 
 10.2 Termination. 

(a) Material Breach. Each Party shall have the right to terminate this Agreement immediately upon written notice to the other
Party if such other Party materially breaches this Agreement and has not cured such breach to the reasonable satisfaction of the non-breaching Party within [***] days after receipt from the non-breaching Party
of written notice specifying the breach and requesting its cure. 
 10.3 Termination for Insolvency. In the event that a Party
(a) files for protection under bankruptcy or insolvency laws, (b) makes an assignment for the benefit of creditors, (c) appoints or suffers appointment of a receiver or trustee over substantially all of its property that is not
discharged within [***] days after such filing, (d) proposes a written agreement of composition or extension of its debts, (e) is a party to any dissolution or liquidation, (f) files a petition under any bankruptcy or insolvency act
or has any such petition filed against that is not discharged within [***] days of the filing thereof, or (g) admits in writing its inability generally to meet its obligations as they fall due in the general course, then the other Party may
terminate this Agreement in its entirety effective immediately upon written notice to such Party. 
 10.4 Purchaser Suspension
Rights. Purchaser shall have the right to suspend delivery by Dynavax of any quantities of CpG Material, without liability, in the event of any of the following occurring, with respect to the clinical trials undertaken with respect to the
Product and, where applicable, with respect to the commercialization of the Product: 
 (a) based on the decision of a
Regulatory Authority or independent trial safety monitoring board those trials are cancelled or suspended for more than one hundred eighty (180) days for reasons directly attributable to the CpG Material; 

  
 25 

 CONFIDENTIAL 
  

 (b) as a result of those trials the CpG Material, or its use in connection with the
Vaccine, is deemed unsafe by a Regulatory Authority; or 
 (c) following the decision of a Regulatory Authority or independent
trial safety monitoring board, the commercialization of the Product is suspended or a recall of the Product is demanded. 
 10.5
Effects of Termination; Survival. Termination or expiration of this Agreement shall not affect the rights or obligations of the Parties under this Agreement that have accrued prior to the date of termination or expiration. Upon termination of
this Agreement (a) for any reason, Purchaser shall pay all undisputed outstanding invoices; and (b) by Purchaser pursuant to Section 10.2(a), Purchaser shall have the right to request that Dynavax manufacture and deliver to Purchaser,
in which case Dynavax shall manufacture and deliver to Purchaser, the CpG Material under all outstanding accepted Purchase Orders on the relevant scheduled delivery dates and Purchaser shall pay Dynavax the Final Payment for such Purchase Orders not
later than [***] days after Purchaser’s acceptance date therefor. Notwithstanding anything to the contrary, the following provisions shall survive any expiration or termination of this Agreement: Article 1 (Definitions), Section 5.2
(Restrictions on Use of CpG Material), Article 6 (Intellectual Property), Article 7 (Confidentiality), Article 9 (Indemnification), Section 10.5 (Effects of Termination; Survival), and Article 11 (General Provisions). 

ARTICLE 11 
 GENERAL
PROVISIONS 
 11.1 Force Majeure. Neither Party shall be liable to the other for any failure to fulfil its obligations
under the Agreement to the extent that such failure is caused by force majeure event. As used in this Section 11.1, a “force majeure event” means any events which a Party could not reasonably have foreseen, prevented, mitigated risks
from, or controlled by reason of the unavoidable, unforeseeable, or uncontrollable nature of such events, including (in each case provided they, or events resulting from them, have the preceding characteristics) fires, floods, earthquakes,
hurricanes, embargoes, shortages, epidemics, pandemics, quarantines, riots, insurrections, civil or foreign wars, or strikes, as well as any other circumstances beyond the reasonable control of the affected Party. The Party affected by the
occurrence of a force majeure event shall (a) promptly inform the other Party thereof and (b) use reasonable efforts to mitigate the consequences of such force majeure event and to remedy the situation and recommence performance as soon as
reasonably practicable. Any timelines affected by a force majeure event shall be extended for a period equal to that of the delay. The affected Party shall provide notice of the start and stop of any force majeure event to the other Party. 

  
 26 

 CONFIDENTIAL 
  

 11.2 Governing Law. This Agreement, and all questions regarding the existence,
validity, interpretation, breach, or performance of this Agreement, shall be governed by, and construed and enforced in accordance with, the laws of the State of New York, United States, without reference to its conflicts of law principles. The
application of the U.N. Convention on Contracts for the International Sale of Goods (1980) is excluded. 
 11.3 Dispute
Resolution. 
 (a) General. Any dispute between the Parties arising out of, in connection with or relating to this
Agreement or any document or instrument delivered in connection herewith (a “Dispute”) shall be resolved pursuant to this Section 11.3. 

(b) Senior Officers. Any Dispute shall first be referred to the Senior Officers of the Parties, who shall confer in good faith
on the resolution of the issue. Any final decision mutually agreed to by the Senior Officers in writing and signed by authorized representatives of the Parties shall be conclusive and binding on the Parties. 

(c) Exclusive Jurisdiction and Venue. If the Senior Officers are not able to agree on the resolution of a Dispute within thirty
(30) days (or such other period of time as mutually agreed by the Senior Officers) after such Dispute was first referred to them, then, if a Party wishes to pursue further resolution of such Dispute, subject to Section 11.3(d) below, such
Dispute shall be subject to the exclusive jurisdiction of the United States District Court for the Southern District of New York (the “Court”). Each Party hereby irrevocably consents to the personal jurisdiction of the Court for any
action, suit or proceeding (other than appeals therefrom) arising out of, in connection with or relating to this Agreement or any document or instrument delivered in connection herewith, agrees not to raise any objection at any time to the laying or
maintaining of the venue of any such action, suit or proceeding in such Court, irrevocably waives any claim that such action, suit or other proceeding has been brought in an inconvenient forum, and further irrevocably waives the right to object,
with respect to such action, suit or other proceeding, that such Court does not have any jurisdiction over such Party. Each Party further agrees that service of any process, summons, notice or document delivered by reputable international overnight
or express courier service to its address set forth in Section 11.5 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any such Court. 

Each Party further agrees that service of any process, summons, notice or document delivered by reputable international overnight or express courier service
to its address set forth in Section 11.5 shall be effective service of process for any action, suit or proceeding brought against it under this Agreement in any Court. 

(d) Interim Relief. Notwithstanding anything herein to the contrary, including Section 11.3(b), nothing in this
Section 11.3 shall preclude either Party from (i) seeking interim or provisional relief, including a temporary restraining order, preliminary injunction, or other interim equitable relief concerning a Dispute in any court of competent
jurisdiction before or after the initiation of a proceeding as set forth in Section 11.3(c), and (ii) the Parties may submit any dispute, controversy, or claim relating to the scope, validity, enforceability or infringement of any
intellectual property before any relevant administrative body, in the country in which such intellectual property was granted or arose without first having complied with the procedures set forth in Section 11.3(c). This Section 11.3(d)
shall be specifically enforceable. 

  
 27 

 CONFIDENTIAL 
  

 11.4 Entire Agreement; Amendment. This Agreement, including the Exhibits, is
both a final expression of the Parties’ agreement and a complete and exclusive statement with respect to all of its terms. This Agreement supersedes all prior and contemporaneous agreements and communications, whether oral, written, or
otherwise, concerning any and all matters contained herein (including the Confidentiality Agreement between the Parties dated 6 April 2020; provided that all “Confidential Information” disclosed or received under such Confidentiality
Agreement shall be deemed “Confidential Information” under this Agreement and subject to the terms and conditions of this Agreement); provided however, that except as set forth in Section 6.8, the Collaboration Agreements shall
continue in full force and effect in accordance with their respective terms. This Agreement may only be modified or supplemented in a writing expressly stated for such purpose and signed by the authorized representatives of the Parties to this
Agreement. No modification to this Agreement will be effected by the acknowledgment or acceptance of any Purchase Order or shipping instruction forms or similar documents containing terms or conditions at variance with or in addition to those set
forth herein. 
 11.5 Notices. Except for any Purchase Orders or any acknowledgement of any Purchase Orders, which will be
transmitted electronically, any notice required or permitted to be given under this Agreement must be in writing in English and delivered either in person, by air mail (postage prepaid) requiring return receipt, or by overnight courier to the Party
to be notified at its address(es) given below, or at any address such Party may designate by prior written notice to the other in accordance with this Section 11.5. Notice shall be deemed sufficiently given for all purposes upon the earliest
of: (a) if delivered in person, the date of actual receipt, (b) if air mailed, on the date of receipt as evidenced by the date on the return receipt, and (c) if delivered by overnight or express courier, the date of receipt as
evidenced by the date on the courier’s receipt. Any such notice shall be deemed to have been given on the Business Day delivered, or if delivered or sent on a non-Business Day, then on the next Business
Day. Each Party may also provide a courtesy copy of any such notice by e-mail (which copy shall not constitute notice). 

If to Purchaser, notices must be addressed to: 

Valneva Scotland Limited 

Oakbank Park Rd 
 Livingston
EH53 0TG 
 United Kingdom 

Attention: Finance Director 

with a copy, which shall not constitute notice, to: 

Valneva SE 
 6 rue Alain Bombard
44800 
 Saint Herblain 

France 
 Attn: General Counsel

 e-mail: [***] 

  
 28 

 CONFIDENTIAL 
  

 If to Valneva Austria, notices must be addressed to: 

Valneva Austria GmbH 
 Campus
Vienna Biocenter 3 
 1030 Vienna 

Austria 
 Attention: The COVID
Programme Director 
 with a copy, which shall not constitute notice, to: 

Valneva SE 
 6 rue Alain Bombard
44800 
 Saint Herblain 

France 
 Attn: General Counsel

 e-mail: [***] 

If to Dynavax, notices must be addressed to: 

Dynavax Technologies Corporation 

2100 Powell Street, Suite 900 

Emeryville, CA 94608 
 USA 

Attn: President and Chief Operating Officer 

with a copy, which shall not constitute notice, to: 

Dynavax Technologies Corporation 

2100 Powell Street, Suite 900 

Emeryville, CA 94608 
 USA 

Attn: General Counsel 

11.6 Assignment. Except as expressly provided hereunder, neither this Agreement nor any rights or obligations hereunder may be
assigned or otherwise transferred by either Party without the prior written consent of the other Party (which consent shall not be unreasonably withheld or conditioned); provided, however, that either Party may assign or otherwise transfer
this Agreement and its rights and obligations hereunder without the other Party’s consent: 
 (a) in
connection with the transfer or sale of all or substantially all of the business or assets of such Party relating to this Agreement to a Third Party, whether by merger, consolidation, divesture, restructure, sale of stock, sale of assets, or
otherwise; or 
 (b) to an Affiliate, provided that no such assignment shall relieve the assigning Party of
its obligations hereunder; or 
 (c) in the case of Purchaser, to the UK Crown or any entity of, or on behalf of, the
UK Crown. 

  
 29 

 CONFIDENTIAL 
  

 The rights and obligations of the Parties under this Agreement shall be binding upon and inure to the benefit
of the successors and permitted assigns of the Parties specified above, and the name of a Party appearing herein will be deemed to include the name of such Party’s successors and permitted assigns to the extent necessary to carry out the intent
of this Section 11.6. Any assignment not in accordance with this Section 11.6 shall be null and void. 
 11.7
Performance by Affiliates. Each Party may discharge any obligations and exercise any right hereunder through any of its Affiliates. Each Party hereby guarantees the performance by its Affiliates of such Party’s obligations under this
Agreement, and shall cause its Affiliates to comply with the provisions of this Agreement in connection with such performance. Any breach by a Party’s Affiliate of any of such Party’s obligations under this Agreement shall be deemed a
breach by such Party, and the other Party may proceed directly against such Party without any obligation to first proceed against such Party’s Affiliate. 

11.8 Further Actions. Each Party agrees to execute, acknowledge, and deliver such further instruments, and to do all such other
acts, as may be necessary or appropriate in order to carry out the purposes and intent of this Agreement. 
 11.9
Severability. In the event that any term of this Agreement is held to be invalid, illegal, or unenforceable, such invalidity, illegality, or unenforceability shall not affect any other portion of this Agreement, and in such case the Parties
shall promptly negotiate in good faith to amend such illegal, invalid, or unenforceable term with a valid, legal, and enforceable term that most closely effectuates the original intent of the Parties. 

11.10 No Waiver. The failure on the part of a Party to enforce, or any delay in enforcing, any right, power, or remedy that such
Party may have under this Agreement shall not constitute a waiver of any such right, power, or remedy, or release the other Party from any obligations under this Agreement, except by a written document signed by the Party against whom such waiver or
release is sought to be enforced. Such written document shall specify the particular matter waived and, if applicable, the relevant period of time. 

11.11 Relationship Between the Parties. The Parties’ relationship, as established
by this Agreement, is solely that of independent contractors. This Agreement does not create any partnership, joint venture, or similar business relationship between the Parties. Neither Party is a legal representative of the other Party and neither
Party can assume or create any obligation, representation, warranty, or guarantee, express or implied, on behalf of the other Party for any purpose whatsoever. 

11.12 Interpretation. The headings of clauses contained in this Agreement preceding the text of the sections, subsections, and
paragraphs hereof are inserted solely for convenience and ease of reference only and shall not constitute any part of this Agreement, or have any effect on its interpretation or construction. All references in this Agreement to the singular shall
include the plural where applicable. Unless otherwise specified, references in this Agreement to any Article shall include all Sections, subsections, and paragraphs in such Article, references to any Section shall include all subsections and
paragraphs in such Section, and references in this Agreement to any subsection shall include all paragraphs in such subsection. The word “including” and similar words means including without limitation. The word “or” means
“and/or” unless the context 

  
 30 

 CONFIDENTIAL 
  

 
dictates otherwise because the subjects of the conjunction are, or are intended to be, mutually exclusive. The words “herein”, “hereof”, and “hereunder” and other
words of similar import refer to this Agreement as a whole and not to any particular Section or other subdivision. All references to days in this Agreement mean calendar days, unless otherwise specified. References to any agreement, contract,
statute, act, or regulation are to that agreement, contract, statute, act, or regulation as amended, modified, or supplemented from time to time in accordance with the terms hereof and thereto. Ambiguities and uncertainties in this Agreement, if
any, shall not be interpreted against either Party, irrespective of which Party may be deemed to have caused the ambiguity or uncertainty to exist. This Agreement has been prepared in the English language and the English language shall control its
interpretation. In addition, all notices required or permitted to be given hereunder, and all written, electronic, oral, or other communications between the Parties regarding this Agreement, shall be in the English language. 

11.13 Counterparts; Electronic or Facsimile Signatures. This Agreement may be executed in two or more counterparts, each of
which shall be an original, but all of which together shall constitute one instrument. This Agreement may be executed and delivered electronically, including by DocuSign, or by facsimile and upon such delivery such electronic or facsimile signature
will be deemed to have the same effect as if the original signature had been delivered to the other Party. 
 {SIGNATURE
PAGE FOLLOWS} 

  
 31 

 CONFIDENTIAL 
  

 IN WITNESS WHEREOF, the
Parties hereto have caused this SUPPLY AGREEMENT to be executed and entered into by their duly authorized representatives as of the Effective Date. 

 

									
	DYNAVAX TECHNOLOGIES CORPORATION	 		 	VALNEVA SCOTLAND LTD.
					
	By:	 	 /s/ David Novack
	 		 	By:	 	 /s/ David Lawrence

	Name:	 	 David Novack
	 		 	Name:	 	 David Lawrence

	Title:	 	 President and COO
	 		 	Title:	 	 Director

					
	Date:	 	 11 September 2020
	 		 	Date:	 	 11 September 2020

					
		 		 		 	By:	 	 /s/ Thomas Lingelbach

		 		 		 	Name:	 	 Thomas Lingelbach

		 		 		 	Title:	 	 Director

					
		 		 		 	Date:	 	 11 September 2020

				
		 		 		 	VALNEVA AUSTRIA GMBH
					
		 		 		 	By:	 	 /s/ David Lawrence

		 		 		 	Name:	 	 David Lawrence

		 		 		 	Title:	 	 Managing Director

					
		 		 		 	Date:	 	 11 September 2020

					
		 		 		 	By:	 	 /s/ Frédéric Jacotot

		 		 		 	Name:	 	 Frédéric Jacotot

		 		 		 	Title:	 	 Managing Director

					
		 		 		 	Date:	 	 11 September 2020

  
 32 

 CONFIDENTIAL 
  

 Exhibit A 

CpG Adjuvant and CpG Material 

Dynavax’s proprietary toll-like receptor 9 (TLR9) agonist adjuvant referred to as CpG 1018 

 

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  

	 	•	 	 [***] 

  
 1 

 CONFIDENTIAL 
  

 Exhibit B 

Initial Forecast in Doses 
 Delivery
schedule in million Doses based on the Dose Assumption (i.e., [***] mg per Dose) Delivery lead time = [***] months ([***] months for first [***] million Doses) 
  

																																	
	 	  	Q4 2020	 	 	Q1 2021	 	 	Q2 2021	 	 	Q3 2021	 	 	Q4 2021	 	  	Q1 2022	 	  	Q2 2022	 	  	Q3 2022	 
									
	 UK Order
	  	 	[***	] 	 	 	[***	] 	 				 				 				  				  				  			
									
	 UK Delivery
	  				 	 	[***	] 	 	 	[***	] 	 	 	[***	] 	 				  				  				  			

 CONFIDENTIAL 
  

 Exhibit C 

Cost per Dose 
 [***] 

[***] 
 [***]

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00326-of-00352.parquet"}]]